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Genetic basis of host susceptibility to infections
Proceedings of the 14th GSK Kurhaus Workshop on Infectious Diseases
Scheveningen, the Netherlands, 8 March 2002
P R E F A C E
The wide variation in the incidence and severity of infectious diseases among individuals in the same population and
between populations may be (largely) due to variation in socioeconomic circumstances, human behaviour and variation
in microbial virulence. However, host susceptibility and severity of infectious diseases in humans can also be linked to
polymorphisms in the human genome. This 14th Kurhaus Workshop on Infectious Diseases explores several important
examples of genetic polymorphisms that have recently been linked to host susceptibility and infection. Although much
remains to be discovered in this field the evidence presented at this Workshop clearly pointed toward the future impact
of genomic information in the management of infectious diseases in individuals as well as in public health.
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A B S T R A C T
Mannose-binding lectin (MBL) is an important element of the innate immune defence system. The protein binds to the
sugars present on many microbial surfaces and subsequently activates the complement system through a family of specific
proteases called the MASPs (MBL-associated serine proteases). Studies of MBL binding to selected Gram-negative organisms
suggest that the lipopolysaccharide (LPS) structure is of primary importance. For a range of clinically relevant organisms
MBL binding leads to activation and cleavage of C4 and C3, suggesting that this is a major pathway for opsonophagocytosis.
MBL deficiency, resulting from three mutations in exon 1 and polymorphisms in the promoter region of the gene, is
associated with both increased susceptibility to infections and autoimmune disease. Recent evidence indicates that the
protein also modulates disease severity, possibly by influencing cytokine production.
I N T R O D U C T I O N
Mannose-binding lectin (MBL) is a pattern recognition
molecule of the innate immune system.1 It belongs to a
family of proteins called the collectins,2-4 in which lectin
(carbohydrate recognition) domains are found in association
with collagenous structures. In man these proteins include
serum MBL, lung surfactant protein A (SP-A) and lung
surfactant protein D (SP-D). Each of these proteins plays
an important role in innate immune defence, but MBL is
of particular interest because it is able to activate the
complement system in an antibody- and C1-independent
manner.
M B L  S T R U C T U R E
MBL has a bouquet-like structure with many similarities
to C1q. However, unlike C1q it can exist as dimers, trimers,
tetramers or hexamers. All higher-order oligomers of
MBL are based on subunits comprising three identical
peptide chains of 32 kDa. Each chain is characterised by a
lectin domain, an -helical coiled-coil hydrophobic neck
region, a collagenous region and a cysteine-rich N-terminal
region.5,6 Three such chains interact to give a collagenous
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The role of mannose-binding lectin in health
and disease
M.W. Turner
Institute of Child Health, University College Londen, Londen, United Kingdom
triple helix,7 but separate at the neck region to give three
independent carbohydrate recognition domains.
MBL is a C-type (calcium-dependent) lectin that is able to
interact with the 3- and 4-hydroxyl groups of various
sugars, including N-acetyl-D-glucosamine, mannose,
N-acetyl-mannosamine, fucose and glucose.8 The repeating
arrays or patterns of sugar groups expressed on microbial
surfaces make ideal targets for MBL binding, since the
three sugar-binding sites of one subunit provide a flat
platform with a constant distance between the individual
binding sites (45 Å for human MBL).9 Because the Kd of
each separate MBL-sugar interaction is relatively low
(10-3 M)10 such simultaneous multiple binding is critical
in order to achieve a high avidity.
M B L  F U N C T I O N
The activation of complement by MBL represents a pathway
which is independent of both the classical and alternative
pathways, but which has similarities to the classical path-
way. In the circulation MBL is found in association with
four structurally related pro-enzymes. These are the MBL-
associated serine proteases (MASPs) 1, 2 and 311-13 and a
truncated version of MASP-2 called MAp 19.14,15 In serum
there is a 20-fold excess of MASP-1 over MBL16 and some
evidence that the enzyme cleaves C3 directly. MASP-2,
which is present at much lower concentrations than
MASP-1, appears to be the more important in complement
activation.12 The available data suggest that MBL – MASP-2
complexes become activated when bound to appropriate
sugar arrays on microbial surfaces.17 The enzyme specificity
of MASP-2 is apparently identical to that of Cl esterase
and results in the sequential cleavage of C4 and C2. The
C4b fragments generated bind covalently either to the MBL
itself or to the nearby microbial surface and act as a focus
for C2 binding/activation. The resultant C4b2a complex has
C3 convertase activity and cleaves C3 in a similar manner
to the C3 convertases of both the classical and alternative
pathways of complement activation (see figure 1). 
been proposed, including cClqR/calreticulin,18 ClqRp
19
and CR1.20,21. However, it is unclear whether MBL acts as
a direct opsonin for micro-organisms22 or simply enhances
other well-established pathways of complement and/or
immunoglobulin receptor-mediated phagocytosis.23
M B L  G E N E T I C S  A N D  P O L Y M O R P H I S M S
Within the human collecting gene cluster mapped to 10q
21-2424 there is a single functional MBL gene comprising
four exons. Exon 1 encodes the signal peptide, a cysteine-
rich region and part of the glycine-rich collagen-like
region. Exon 2 encodes the remainder of the collagenous
region, whilst exon 3 encodes for the -helical coiled-coil
neck region. The fourth exon encodes the C-terminal
carbohydrate recognition domain. Upstream of the MBL
gene are a number of regulatory, promoter elements which
are believed to enhance MBL transcription approximately
threefold during acute-phase responses.5,6
MBL deficiency results predominantly from three single-
point gene mutations in codons 52, 54 and 57 of exon 1 of
the MBL gene.25 These are commonly referred to as the
D, B and C variants, with A indicating wild type. The B
variant mutation occurs in approximately 26% of
Caucasians, whereas the C variant mutation is characteristic
of sub-Saharan African populations in whom it may reach
frequencies of 50 to 60%. Both the B and C mutations
result in the substitution of a dicarboxylic acid for an axial
glycine, and this impairs correct oligomerisation.26 In
addition to the above structural gene mutations, several
polymorphisms exist within the promoter region of the
MBL gene. These polymorphisms are the H/L, X/Y and P/Q
loci at positions -550, -221 and +4 of the MBL gene.27 The
alleles expressed at these loci are in linkage disequilibrium
and four promoter haplotypes (LXP, LYP, LYQ and HYP)
are commonly found. Of these the HYP haplotype is
associated with high MBL levels, whereas the LXP haplo-
type is found in association with low levels of the protein.28
The HXP haplotype has never been unequivocally iden-
tified.
The three structural gene mutations are also in linkage
disequilibrium with the promoter polymorphisms and
every individual expresses two of the following seven
possible haplotypes – HYPA, LYQA, LYPA, LXPA, LYPB,
LYQC and HYPD. The frequencies of these haplotypes
differ markedly between different population groups.27
Our observations on the distribution of the B and C
alleles in African and non-African populations led us to
suggest that the two mutations probably arose independently
after the migration of hominids out of Africa some
100,000 to 150,000 years ago.26 It is of interest that none
S U P P L E M E N T  M A R C H  2 0 0 4 ,  V O L .  6 2 ,  N O .  3
5
MBL
C3b
MASP-2
C4b2a
(C3 convertase)
Figure 1
Mannose-binding lectin (MBL) complexed with the
pro-enzyme MASP-2 is shown binding to a sugar array
on the surface of a micro-organism
The MASP-2 becomes activated and is able to cleave sequentially both
C4 and C2. A complex of the major fragments of these components,
C4b2a, is a functionally-active C3-cleaving enzyme (or C3-convertase)
and is able to generate large amounts of C3b, an important opsonin.
The C3b generated by the MBL – MASP pathway is fed
into the positive feedback amplification loop of complement
activation and results in the deposition of large amounts
of opsonic C3b on the microbial surface.
There is some evidence to suggest that MBL is able to
interact directly with cell surface receptors and promote
opsonophagocytosis and other immune processes.
Several putative MBL-binding proteins/receptors have
of the three structural gene mutations were introduced
into Australia at the time of first settlement (c. 50,000
years ago)29 whereas the B mutation was introduced into
North America at the time of the last glaciation (c. 20,000
years ago). This suggests that the B mutation may have
arisen between 20,000 and 50,000 years ago on the LYP
promoter background.29
M B L  B I N D I N G  T O  M I C R O - O R G A N I S M S
We have used flow cytometry to study MBL binding to a
range of clinically relevant pathogens isolated from immuno-
compromised children and found large differences.30
Some organisms such as Candida albicans, -haemolytic
Group A Streptococci and Staphylococcus aureus have
consistently exhibited high binding, whereas others such
as Clostridium sp., Pseudomonas aeruginosa, Staphylococcus
epidermidis, -haemolytic Streptococcus Group B and
Streptococcus pneumoniae appear not to bind the protein.
In between are other organisms with more variable patterns
of binding, such as Klebsiella species and Escherichia coli.
In our present state of knowledge such heterogeneity is
not readily explained, and it has prompted us to explore in
more detail the determinants of MBL binding to bacteria. 
To this end we have studied the effect of LPS structure 
on MBL attachment to both Salmonella enterica serovar
Typhimurium31 and to the human pathogens Neisseria
gonorrhoeae31 and N. meningitidis (serogroups B and C).32,33
In particular, we have examined the relative importance of
LPS structure and capsule in determining MBL binding to
the serogroup-B meningococcus. It was observed that the
absence of sialic acid from the LOS of Neisseria meningitidis
serogroup B,32 serogroup C33 and Neisseria gonorrhoeae31
permitted MBL to bind to each of these organisms. In
contrast, MBL appeared to bind very poorly or not at all to
organisms with sialylated LOS. In the case of Salmonella
species, organisms of the rough chemotype (not expressing
the O-antigen) showed MBL binding whereas organisms
with the smooth chemotype and expressing the O-antigen
exhibited little or no MBL binding.31 These results suggest
that LPS structure exerts a major influence on MBL attach-
ment to bacteria.
T H E  R O L E  O F  M B L  I N  D I S E A S E  
The immunological significance of MBL deficiency was
initially established in children,34 but there are now
numerous studies indicating a role for the lectin in later
life and supporting the notion that it should be considered
as an ante-antibody, a humoral factor playing a critical role
in immune defence before the production of antibodies.1
There is increasing evidence that MBL – disease associations
are very complex. At present the topic may be considered
under the following separate headings: (a) MBL and disease
susceptibility, (b) MBL and disease severity and (c) inappro-
priate activation of the MBL – MASP pathway.
M B L  A N D  D I S E A S E  S U S C E P T I B I L I T Y
Several studies have shown that deficiency of MBL is
associated with an increased overall susceptibility to
infectious disease.35,36 In terms of community health this
may go some way towards explaining why some individuals
suffer more infections than others.37,38 However, in a
hospital setting it also appears that MBL deficiency has
an important influence on the occurrence and duration of
febrile neutropenic episodes in children with malignancy.39
In addition to such increased generalised susceptibility,
other studies have identified an increased susceptibility to
infection by specific pathogens in MBL-deficient individuals,
including human immunodeficiency virus,40,41 Plasmodium
falciparum,42 Cryptosporidium parvum43 and N. meningitides.44
However, in the case of intracellular parasites (e.g. Leish-
mania) it appears that MBL deficiency may actually protect
against disease. It is suggested that since such parasites
exploit C3b opsonisation to facilitate uptake by the C3
receptors of macrophages and thereby gain entry to those
cells, any reduction in the complement-activating function
of the host may help reduce the probability of infection.
The most convincing evidence to date of such a mechanism
is a study of patients with visceral leishmaniasis in Brazil.45
The median MBL level of these patients was significantly
higher than that of healthy individuals and MBL mutations
were significantly more common in the healthy controls.
In addition to the above reports of associations with
infectious disease, there have been several investigations
of possible associations between MBL deficiency and
susceptibility to autoimmune disease. There is strong
evidence of such an association in the case of systemic
lupus erythematosus (SLE). Cohorts of British,46 Hong Kong
Chinese,47 American Black48 and Spanish49 SLE patients
have all shown evidence of an increased frequency of
mutant MBL alleles or deficiency of the serum protein.
The interpretation of these findings has usually reiterated
the hypothesis proposed in relation to components of the
classical complement pathway, namely that an impairment
of the mechanisms involved in the removal of immune
complexes may predispose to the development of auto-
immune disease.
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M B L  A N D  D I S E A S E  S E V E R I T Y
In addition to the mounting evidence that MBL deficiency
influences susceptibility to disease there have been several
reports suggesting that the protein can also modulate dis-
ease severity. In the field of autoimmunity there is evidence
of such a modulatory role for MBL, and recent studies
from two centres have indicated that MBL variant alleles
are associated with both severity and early onset of disease
in patients with rheumatoid arthritis.50-53 The mechanism
by which MBL exerts such effects is unclear but our recent
studies on Neisseria meningitidis54 suggest that one possible
pathway may be through cytokine modulation. When
N. meningitidis organisms were incubated with increasing
concentrations of MBL and added to whole blood from an
MBL-deficient donor, the release of the cytokines TNF-,
IL-1b and IL-6 from monocytes was enhanced at lower MBL
concentrations (<4 g/ml) but reduced at higher concen-
trations (>4 g/ml). Further work is required to establish
whether this complex modulation of proinflammatory
cytokine release occurs with other infectious organisms.
I N A P P R O P R I A T E  A C T I V A T I O N  O F  
T H E  L E C T I N  P A T H W A Y
Pathology associated with unregulated or inappropriate
activation of the classical and alternative pathways of
complement has been well documented over many years
and it is to be expected that similar reports involving the
MBL – MASP pathway will appear. At the time of writing
there have been a small number of such studies in the
fields of renal disease and reperfusion injury.
In one of the first studies in this area Endo and colleagues
reported that MBL – MASP activation contributed to the
glomerular damage observed in a significant number of
patients with IgA nephropathy.55 However, in another study
of renal biopsies from several patients with different forms
of glomerulonephritis, Lhotta and co-workers claimed that
the MBL deposition observed was of minor importance.56
Subsequent studies have described MBL deposition in the
glomeruli of a patient with poststreptococcal glomerulo-
nephritis57 and in ten patients with Henoch-Schönlein
purpura nephritis.58 Much further work is required to
evaluate the role of the MBL – MASP system in these
disorders.
Recently MBL depletion and anti-human MBL monoclonal
antibodies have been used to establish a role for the
MBL – MASP pathway in initiating the complement
activation which occurs following hypoxia-reoxygenation
of human endothelial cells.59 In a separate study from the
same group the MBL – MASP pathway was shown to be
activated in rats following myocardial ischaemia reperfusion,
suggesting that it is implicated in the subsequent tissue
injury.60 Blockade of the lectin pathway with inhibitory
monoclonal antibodies protected the heart from ischaemia
reperfusion, and suggests that this therapeutic approach
should be explored in human patients.
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Discussion following lecture by M.W. Turner
Verbrugh: This topic is now open for discussion. I would
first like to discuss the binding of mannose-binding lectin
(MBL) to the surfaces of micro-organisms, one of the
first observations that you talked about. There was quite
some heterogeneity in binding between species of micro-
organisms and within species. You did not say much
about that, except that there was some focal site of binding,
but is there anything else that you or anybody else in this
room may add on that phenomenon? Because that seems
to be important for MBL’s mode of action.
Turner: Well, we have looked at both Neisseria meningitidis
B and C and a range of isogenic mutants of salmonella.
The bulk of the work that has been published has been done
in those organisms. There is a consistent story that the
presence of sialic acid strongly inhibits the binding of MBL.
But there are problems with some organisms regarding the
expression of sugars. Sometimes there will be a terminal
sugar accessible that ought to bind MBL and yet we do not
see any binding. So I must say that there is still an awful
lot of work to be done. We cannot simplistically take the
sugar structure that has been published for a particular
mutant and say with any certainty, without doing the
experiments, that MBL will bind or not. The fact is that
sugars are not fixed in space. They are waving around and
there are all sorts of stereo configurations that need to be
taken into account. It is more complicated than simple
linear sequences would suggest. Not a very satisfactory
answer, but I am afraid that is the way it is.
Verbrugh: Because microbes are also rather dynamic
structures where cell walls are broken down and syn-
thesised, and you do show some binding at certain sites
of the cell surface, but not at other sites, that may have
to do with the structuring of the cell wall at the time in
that organism.
Turner: I should also say, by the way, that the flow cytometry
is not that sensitive, because when we came to do the
immuno gold staining, we found that the sialylated
parent organism of Neisseria meningitidis serogroup B
did show some foci of binding but in much lower num-
bers and with the serogroup C, the 8O26 mutant, which
we can exogenously sialylate. We have data showing that
a little bit of binding does occur. So obviously, whatever
one says about the flow-cytometry results, one has to
bear in mind that there is a sensitivity issue there and
that one can push that a little bit further by using better
techniques.
Van Strijp: One thing that would be far more sensitive is
looking at it functionally. Is there complement activation,
yes or no? Is there a correlation between the binding
assay and complement activation in all of these organisms
that you showed?
Turner: That is a good question. First of all, two things we
always do are to worry a bit about the possibility that the
binding we see may be going in the opposite direction and
that there is some lectin on the surface of the organism
recognising a sugar on the MBL, because it is a sugar-bearing
molecule itself. So we always do an EDTA chelation experiment
to show that the binding is a calcium-dependent one. And
we always do an inhibition with an inositol glucosamine
or mannose and show that that competes. So we have two
controls in all these systems to help us confirm that it
really is a C-type lectin interaction. Whenever we looked
for C4 binding, which we can do with purified C4, we
always found an absolute correlation. If it binds MBL, we
can go on. We have got data to show those strains which
bind MBL, bind C4, and there is a strong correlation
between the levels of binding, so the answer is, yes, there
is a correlation. We have yet to see an exception to that.
Van Strijp: There are people stating that the old-fashioned
alternative pathway may no longer exist and that most of
it is mediated by MBL. Do you think that is true? 
Turner: The thing about the alternative pathway, the real
important point about it, is the amplification loop, which
certainly exists. I think the only point at issue is whether
there is circulating this small amount of precleaved C3
which will pick up factor B. Even Peter Lackman, who
was very positive about that concept in the 1980s, was
very happy to think that it might well be MBL causing
some of that entrée into the system. I do not have a
strong view on that, but I think the fact is that both
MBL-associated serine proteases (MASP) and MBL have
been shown in quite primitive organisms, and even in
urochordates all the MASP proteins are present. So it is
an ancient system, there is no doubt about it. Whether or
not there is a separate mechanism whereby organisms
can become coated by alternative pathway components
without MBL playing a role, I do not know.
Degener: In your experiments you have probably worked
with MBLs in a solution with a bacterial inoculum, but in
the human body, or in the animal experiment, where
does the binding take place then? Is that at the level of
mucous membranes or is there anything more needed
before the binding to MBLs takes place, for instance
adherence of bacteria to a membrane?
Turner: We can say that the protein is essentially an intra-
vascular protein most of the time, but in the presence of
inflammation it certainly gets extravascular. It is present
in the synovial fluids of rheumatoid arthritis patients for
example, it is present in jejunal secretions of AIDS
patients with cryptosporidial diarrhoea. We made Western
blots of such aspirates and proved MBL to be there. So it
gets to some mucosal surfaces when there is inflammation,
but I do not think it would normally be present at such
sites. Two other members of the same family, the collectin
family, are lung surfactant protein A and protein D. Many
like to think of them as innate immune equivalents of
IgA on mucosal surfaces. The other area where there has
been some work suggesting it might get into mucosal
surfaces is with cystic fibrosis, because again you would
not expect it to play any role at all in that disease. But there
are data to suggest that it does get into alveolar fluids. 
De Vries: You said that there might be some discussion
about the suggested selective advantage for the mutations.
And you had two possible explanations. One was the
decreased complement-mediated immunopathology and
the other was the decreased invasion of intracellular
parasites. Those are quite testable hypotheses. Is there
any data on the subject?
Turner: Well, on the question of the parasites there was a
paper in Infection and Immunity last year from Alan
Ezekowitz collaborating with a group in Brazil. MBL
binding to Leishmania has been directly demonstrated to
the premastigotes. But population studies in Brazilians
with and without Leishmania support the concept that
having the mutation protects against leishmaniasis.
There is a small population study with that disease
which does support it. 
De Vries: That is the outcome. But is there any evidence in
that study or in any other related study that the mutation
decreases the invasion by Leishmania parasites for instance
of macrophages?
Turner: Not that I am aware of.
De Vries: And about the complement-mediated immuno-
pathology?
Turner: There is no direct data there, but there is with C6
deficiencies some very good work from South Africa. In the
Cape C6 deficiency is very common among the coloured
population. These people are more susceptible to Neisserial
infections, but they are far less likely to die of those
infections. Many years ago Ross and Denton suggested
that this is a possible explanation of the fact that they are
not activating the complement system through to the end
of the lytic pathway, and therefore not releasing the
mediators which are so damaging, and that this might be
an advantage for them in their particular environment.
So it is by analogy with that C6 deficiency story that this
suggestion has been put forward. Obviously, MBL should
be regarded as a complement component, there is no
question about that. So it is not an outrageous extrapolation
to think of it in the same sort of way, but there is no more
direct supportive data.
Vandenbroucke: The mutation changes the structure of the
protein, you said. I was wondering when you said MBL
deficiency, because you also said that neutropenic patients
have lower levels. What does this mean? Does it mean a
less active MBL, or does it mean lower levels of protein?
In other words, if you want to study MBL deficiency, should
we look at the genes, should we look at active protein or
should we look at protein levels?
Turner: Good question. We believe that it is advantageous
to both genotype and measure the protein levels. There is
detectable protein in individuals with the mutations. But
what there is not, is higher-order oligomers, which is
absolutely critical for MBL function. If you cannot build
it up to those higher-order structures, then you have a
functional deficiency. But if you analyse what is circulating
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by SDS page, for example, from someone who is homo-
zygous for a mutation compared with my own MBL,
which shows normal levels, you can see that there is a
spike in the monomeric region in the person with the
homozygous mutation and then a series of higher-order
oligomers in my serum. So there is detectable protein
there, but it is functionally lousy protein.
Appelmelk: The protein is evidently rather promiscuously
binding to a variety of sugars. We as humans are full of
high-mannose chains. So why are we not killed by MBL?
When there is flexibility, you only need mannose. Why do
we stay alive?
Turner: I think there are two possible answers to that.
First of all, we tend to cap sugars with sialic acid on most
cell surfaces. As a generalisation, I think you would agree
that most oligosaccharide chains on human cell surfaces,
protein oligosaccharides and so on, are terminating with
sialic acid. Secondly, the sorts of characteristic repeating
sugars that one sees on Candida for example, with mannan
particularly, are much less commonly seen on mammalian
cell surfaces. So the fact of the matter is, you have to have
a repeating array of sugar groups. It is about this position
and separation between them that the MBL is beautifully
organised to respond to.
Kullberg: I am still intrigued by the Leishmania issue,
because when there is a 40% incidence of polymorphism,
one would think that there would be a strong selection
pressure to keep these people in the population.
Leishmaniasis obviously is not a disease that occurs
everywhere, which would lead to this selection. So would
not the Leishmania story act as a paradigm for other
intracellular organisms? And the first one you would
think of is M. tuberculosis, and maybe Salmonella may
have a large impact. Are there any studies on that?
Turner: The reason why I have not discussed other
organisms is because it is at this stage a rather confusing
story. There are groups working on both Mycobacterium
tuberculosis and leprosy, and initially the data seemed to
be supporting the hypothesis, but I have recently examined
a thesis from the University of Hong Kong. There was a
large cohort of Chinese patients with tuberculosis, and
instead of those individuals having the expected high
frequency of wild-type MBL genotypes, in fact there was
an increased frequency of mutations. It was against the
hypothesis. I am again not going to put my neck on the
block and say, I am totally wedded to the concept, because
there are enough worrying stories coming through to make
me a bit reserved on that front. Obviously, other diseases
have also been considered: malaria was a candidate very
early on because of its high incidence in Africa. The
frequency obviously varies enormously around the world,
as you saw, but what is very striking is that it is in the
tropical regions of the world that we get the highest fre-
quencies. I personally have not worked on this at all. I am
just acting as a mouthpiece for some of the work of
others. It is an extremely interesting question, because
clearly the mutations have arisen independently of each
other, the 57 and the 54 mutation, in different parts of the
world and then both have risen to high frequencies in the
population. It is quite a striking thing that that should
have happened. It does not seem very logical that it is
simply genetic drift, and that is really about as far as I can
go at this stage. The malaria story is equally confused.
There is one study by Bellamy in The Gambia which came
to the conclusion that there was no strong association.1
Another study by a German group came to the contrary
view. But that was in a much smaller cohort.
Kullberg: The other question is about the pathophysiology
of this mechanism. Do we really know that the binding of
a micro-organism like Leishmania and the subsequent
invasion is the cause, or might it be that the macrophage
activation is playing a role through differences in cytokine
induction, which also would explain this fact?
Turner: I agree with you there.
R E F E R E N C E
1. Bellamy R. Identifying genetic susceptibility for tuberculosis in Africans: a
combined approach using a candidate gene and a genome-wide screen.
Clin Sci (Lond) 2000;98:245-50. 
expression. IFN- acts in an autocrine/paracrine manner
to activate the transcription factor STAT1.10 TLR4-dependent
STAT1 activation, in combination with NF-B, results in
the expression of several genes that mediate host responses
against bacterial pathogens. These include iNOS, IL-12p40,
IL-6, and several chemokines.10
Given the spread of drug-resistant Mtb strains, there is a
pressing need to develop treatments that augment host
innate immunity rather than to rely on new antibiotics.
One novel approach would be to develop therapeutics
that antagonise TLR proteins. This has been accomplished
for one TLR4 agonist, Gram-negative bacterial lipopoly-
saccharide (LPS) and its pharmacophore lipid A. Three
lipid A analogues, lipid IVA, Rhodobacter sphaeroides lipid
A (RSLA) and E5531 have all been reported to function as
LPS antagonists when tested both in vitro and in vivo.11-13
We subsequently demonstrated that RSLA could also block
signalling by a TLR2 agonist, the mycobacterial glycolipid
lipoarabinomannan.14 Together, these data suggest that
certain lipid A structural antagonists are capable of blocking
TLR-dependent activation by molecules that are chemically
dissimilar to LPS. We later showed that the synthetic lipid
I N T R O D U C T I O N
Infection of macrophages with mycobacteria is accompanied
by activation of the transcription factor NF-B, secretion of
inflammatory mediators (e.g. TNF-, IL-1b), release of the
reactive nitrogen intermediate nitric oxide (NO), and secretion
of several chemokines.1 Until recently, the signalling pathways
that elicit the production of these mediators have remained
unknown. Members of the mammalian Toll-like receptor
(TLR) family have been implicated in the activation of macro-
phages by a variety of chemically diverse bacterial products.2,3
We previously demonstrated that viable M. tuberculosis (Mtb)
bacilli contain distinct ligands that activate cells via TLR2
and TLR4, whereas heat-killed Mtb failed to activate cells
via TLR4.4 In contrast, M. avium appears to lack any TLR4
agonists.5 Several purified mycobacterial products have
now been identified as TLR2 agonists, including arabinose-
capped lipoarabinomannan,6 dimannosylated phosphatidy-
linosito,7 and the 19 kDa lipoprotein antigen.8 The identity
of the Mtb TLR4 agonist remains unknown. Interestingly,
TLR2 agonists activate macrophages to express only some
of target genes activated by TLR4 agonists.7,9 This difference
is due, at least in part, to the capacity of TLR4 agonists,
but not TLR2 agonists, to induce -interferon (IFN-)
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Toll-like receptors contribute to host 
responses against mycobacterial infection
M.J. Fenton, K.A. Heldwein
Boston University School of Medicine, the Pulmonary Center, Boston, USA
A B S T R A C T
Mammalian toll-like receptor (TLR) proteins are pattern recognition receptors that mediate cellular activation by a wide
variety of bacterial products. TLR activation leads to the expression of numerous mediators of innate immunity. We used
the nonpathogenic mycobacterium M. bovis BCG (BCG) to define the roles of TLR proteins in the normal development
of an immune response against the bacilli. We found that TLR2-/- mice were unable to effectively control the growth of
BCG in vivo, compared with normal and TLR4-/- mice. Furthermore, splenic T cells isolated from infected TLR4-/- mice
could proliferate in vitro following antigen challenge, but were unable to generate a strong Th1-type response. In contrast,
splenic T cells isolated from infected TLR2-/- mice could neither proliferate in vitro following antigen challenge nor
generate a strong Th1-type response. Together, these studies indicate that TLR proteins participate in the development of
both innate and adaptive immune responses.
A-like antagonist E5531 could block TLR4-dependent
signalling induced by Mtb. E5531 could inhibit selected
Mtb-induced macrophage responses, namely apoptosis
and TNF- secretion, but it did not block Mtb-induced NO
production.15 Subsequent studies revealed that induction of
NO production by Mtb was mediated by a TLR-independent
mechanism15 (and unpublished observations). This
underscores the concept that while purified bacterial TLR
agonists can activate macrophages to express a variety of
proinflammatory mediators in vitro, this is not predictive of
TLR-dependent macrophage activation by intact bacteria.
Here we have sought to determine the relative contributions
of both TLR2 and TLR4 to innate and adaptive immune
responses. In these studies we have used the nonpathogenic
mycobacterium BCG to investigate the role of TLR proteins
in host immune defence in vivo. We reasoned that the use
of BCG would allow us to examine the contributions of TLR
proteins to the normal development of host immunity in
the absence of mycobacterial virulence factors that corrupt
the normal development of these host responses.
M E T H O D S  A N D  M A T E R I A L S
Reagents
M. bovis BCG (ATCC 35734) was purchased from the
ATCC. Bacteria were grown in LPS-free Middlebrook
7H9 liquid medium, supplemented with AODC, Tween
80, and glycerol. Cultures were grown to a density of 0.5
to 0.6 (OD620). Numbers of BCG per ml of culture were
determined by colony counting. 
Animals and cells
TLR2-/- and TLR4-/- mice (female, 5 to 7 weeks old) were
provided by Dr Shuzio Akira (Osaka University), and
have been previously described.16 These mice had been
previously backbred onto a C57Bl/6 background for four
generations prior to their use in these studies. Inbred
C57Bl/6 mice were used as control animals.
Thioglycollate-elicited peritoneal exudate macrophages
were isolated from uninfected mice, and cultured in vitro,
as we have previously described.6 Each mouse was infected
with 106 CFU of M. bovis BCG by intraperitoneal injection,
and sacrificed 14 days later. Spleens were removed from
the infected mice, and total splenocytes were prepared for
culture in vitro, as previously described. Contaminating
LPS levels in all media components were <10 pg/ml final
concentration as measured by Limulus amebocyte lysate
kit (BioWhittaker).
Measurements of cytokine production by macrophages 
in vitro
Peritoneal macrophages from TLR2-/-, TLR4-/- and normal
mice were infected in vitro (5 BCG per macrophage) with
live BCG for 18 hours. The culture supernatants were
removed, filtered to remove any BCG, and then cytokine
levels were measured using specific ELISA kits, as
recommended by the manufacturer (R&D Systems and
Pharmingen).
Measurement of bacterial loads in the lung
Lungs removed from infected mice were homogenised in
a sterile blender, using a lysis buffer consisting of sterile
water containing 0.025% SDS. Homogenates were diluted
in the lysis buffer, and 1 ml aliquots were cultured on
Middlebrook 7H11 agar plates supplemented with glycerol,
L-arginine and cycloheximide (10 mg/ml). Colonies were
counted 14 days later.
Splenic T cell restimulation assay
Spleens were recovered from uninfected and BCG-infected
mice 14 days after inoculation. Total splenocytes were
obtained by tissue disruption between sterile frosted glass
slides, and erythrocytes were removed by lysis in Tris-
buffered ammonium chloride (Sigma). Splenocytes were
then cultured in 96 well plates (5 x 105 cells/well) in the
presence or absence of heat-killed BCG (103 CFU/well).
For proliferation measurements, splenocytes were cultured
for two additional days and pulsed with 3H thymidine
(1 mCi/well) eight hours prior to harvesting. Cells were
harvested using an automated cell harvester (Skatron
Instruments) and incorporation of radiolabelled thymidine
was measured by scintillation counting. For cytokine
secretion, splenocytes were cultured for three additional
days. Culture supernatants were then recovered and specific
cytokine levels measured by ELISA.
R E S U L T S  A N D  D I S C U S S I O N
TLR proteins are necessary for specific macrophage
responses to BCG in vitro
Peritoneal macrophages from TLR2-/-, TLR4-/- and normal
mice were infected in vitro with live BCG for 18 hours.
Cytokine levels in the culture supernatants were measured
using ELISA and the Greiss assay respectively. As shown
in figure 1, BCG-induced TNF- and IL-6 secretion was
substantially lower in the TLR2-/- macrophages compared
with both TLR4-/- and normal macrophages. In contrast,
secretion of IL-12p70 was similar in BCG-stimulated
macrophages from all three mouse strains examined.
This suggests that TLR2, but not TLR4, is necessary for
BCG-induced TNF- and IL-6 production, whereas IL-12
production does not depend on these TLR proteins. In these
experiments, TNF- production was strongly dependent
on the presence of TLR2. Numerous investigators have
shown that TNF- expression in macrophages can be
induced using purified TLR2 agonists.6,17-19 Intact bacteria,
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different mycobacterial species are likely to dictate which
TLR protein is most necessary for the induction of TNF-
expression. We had previously shown that Mtb possesses
both TLR2 and TLR4 agonists, and that blocking TLR4
signalling with the lipid A-like LPS antagonist E5531 largely
blocked TNF- secretion induced by Mtb.15 In contrast
M. avium does not appear to be capable of activating cells
via TLR4.5 It has been reported that BCG possess both TLR2
and TLR4 agonists,20 but the relative abundance of these
agonists had not been determined. We hypothesise that
BCG express lower levels (or fewer types) of TLR4 agonists
than Mtb. Similarly, BCG may express higher levels (or more
types) of TLR2 agonists, compared with Mtb. In either case,
this could explain why TLR4 is not necessary for macrophage
activation by BCG. In contrast to TNF- and IL-6, IL-12
secretion by BCG-stimulated macrophages did not depend
on the presence of TLR2 or TLR4. This finding was un-
expected, but is reminiscent of Mtb-induced NO production,
which is independent of TLR proteins.15 It remains to be
formally determined whether BCG-induced IL-12 production,
like NO production, is also mediated by a TLR-independent
mechanism.
TLR2 is necessary for resistance to mycobacterial 
infection in vivo
TLR2-/-, TLR4-/- and normal mice were infected with live
BCG for 14 days. The lungs were then removed and the
number of bacteria in the tissues was counted. As shown
in figure 2, the lungs from infected TLR2-/- mice contained
more BCG bacilli than lungs from TLR4-/- and control mice.
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Figure 1
Cytokine production by normal and TLR-deficient
macrophages stimulated with BCG
Thioglycollate-elicited peritoneal macrophages (5 x 105 cells/well) from
wild-type, TLR2-/- and TLR4-/- mice were stimulated with live BCG
(five bacilli/macrophage) for 24 hours, and supernatants assayed for
TNF- (A), IL-6 (B) and IL-12p70 (C) by quantitative ELISA. Data are
presented as the mean values of triplicate wells ± SD. Results are
representative of duplicate experiments.
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Figure 2
Bacterial loads in the lungs of normal and TLR-deficient
mice infected with BCG
Normal and TLR-deficient mice were infected intraperitoneally with
106 CFU M. bovis BCG, and the lungs were harvested 14 days later.
Lung homogenates were then prepared, diluted, and cultured on
Middlebrook 7H11 agar plates for colony counting. Data are presented
as mean of lung CFUs from three mice per genotype ± SEM. Results
are representative of duplicate experiments.
such as Gram-negative organisms and Mtb, possess both
TLR2 and TLR4 agonists, although it is likely that the
relative expression of these agonists can vary greatly. Thus,
the relative levels of TLR2 and TLR4 agonists expressed by
Both normal and TLR4-deficient mice were fully capable of
controlling the infection. Thus, the absence of TLR2 led
to permissive growth of BCG in the lung. This finding is
consistent with the inability of TLR2-/- macrophages to secrete
substantial amounts of TNF- following BCG challenge
in vitro (figure 1). Studies performed using TNF--/- mice
have demonstrated the importance of TNF- in controlling
mycobacterial growth in vivo.21 It remains to be determined
whether diminished production of TNF- is responsible
for the lack of mycobacterial growth control in the TLR2-/-
mice. These data do indicate that TLR2 is necessary to
generate an effective host response against mycobacterial
infection. These findings do not completely exclude a role for
TLR4 in the host response against mycobacterial infection.
Our studies shown here used a background mouse strain
that is genetically resistant to mycobacterial infection (i.e.
C57Bl/6), as well as a relatively low inoculum of BCG.
Preliminary studies performed using a mouse strain that
is genetically sensitive to mycobacterial infection and lacks
functional TLR4 (i.e. C3H/HeJ mice) have revealed that TLR4
does indeed contribute to the resistance to BCG infection
in vivo (SN Vogel and MJF, unpublished observations).
Furthermore, this protective role for TLR4 was only observed
using a higher inoculum of BCG (>107 CFU/mouse).
Splenic T cells from both TLR2-/- and TLR4-/- mice fail to
generate a potent Th1-type response in vitro
In order to characterise TLR-dependent control of BCG
growth in vivo, we sought to determine whether TLR-
deficient mice failed to elicit an effective innate and/or
adaptive immune response following BCG infection. To
test these possibilities, we isolated total splenocytes from
uninfected and BCG-infected normal and TLR-deficient
mice. Splenic T cells were then stimulated in vitro with
heat-killed BCG as a source of antigen. Activation of the
T cells was assessed 48 hours later by measuring both
cytokine production and T-cell proliferation (3H thymidine
incorporation). As shown in figure 3, splenocytes isolated
from uninfected mice did not respond to antigenic stimu-
lus, as measured by either cytokine production or T-cell
proliferation. In contrast, normal splenocytes from infected
normal mice secreted IFN- following antigenic stimulation.
This IFN- production was not observed using splenocytes
from infected TLR2-/- or TLR4-/- mice. These findings
suggest that TLR-deficient splenocytes fail to develop a
potent Th1-type response in vitro. We do not believe that
this failure to secrete IFN- represents a skewing of Th
responses, as antigen-stimulated splenocytes from infected
normal and TLR-deficient mice did not secrete measurable
amounts of IL-4 or IL-5 in vitro (data not shown). In
subsequent studies, we examined T-cell proliferation in
vitro and observed that cells from normal and TLR4-/-
mice proliferated in response to antigenic stimulation,
whereas cells from TLR2-/- mice did not (figure 3B). Taken
together, these data suggest that TLR2 and TLR4 contribute
in a fundamentally distinct manner to the development of
an effective Th1 response. Antigen-specific T cells are
generated in BCG-infected TLR4-/- mice, as indicated by
the proliferation of these cells in vitro following antigenic
challenge. Nevertheless, these T cells fail to develop into
effective Th1 responder cells, as indicated by the absence
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Figure 3
Antigen-dependent activation of splenocytes from BCG-
infected normal and TLR-deficient mice
Splenocytes isolated from uninfected and M. bovis BCG-infected mice
were cultured (5 x 105 splenocytes/well) in the presence or absence of
heat-killed BCG (103 CFU/well). (A) After three days, culture supernatants
were harvested and IFN- levels were measured by specific ELISA. (B)
After two days in culture, splenocytes were pulsed with 3H-thymidine for
eight hours. Background values of isotope incorporation in unstimulated
cells were subtracted from values of stimulated cells, and data are
expressed as a ratio of specific isotope incorporation in stimulated cells
from infected mice over uninfected mice. Triplicate wells of cells from
each mouse were assayed. Data are presented as the mean of values
from three uninfected or three infected mice per genotype ± SEM.
Results are representative of duplicate experiments.
of IFN- secretion. This is not a consequence of skewing
towards a Th2 phenotype, as there is no increase in IL-4
and IL-5 production by the antigen-stimulated TLR4-/-
splenocytes. Thus, the immune defect in these cells appears
to come from the inability of Th0 cells to commit to a
Th1 phenotype. It should be noted that the absence of a
strong Th1 response did not detract from the ability of
TLR4-/- mice to control BCG infection in vivo (figure 2).
This may be due, in part, to effective innate immunity (as
evidenced by normal proinflammatory cytokine production,
figure 1) additional to Th1-independent adaptive immunity.
Furthermore, Th1 responses may not be absent in these
mice, only diminished relative to control animals.
The finding that TLR2-/- splenocytes failed to both proliferate
and secrete IFN- following antigenic challenge in vitro
contrasts with the phenotype of the TLR4-/- cells. The BCG-
infected TLR2-/- mice appear to possess a defect in the
development of antigen-specific T cells. The inability of
TLR2-deficient cells to secrete IFN- would then simply
be a consequence of the lack of antigen-responsive T cells,
rather than (or in addition to) a defect in Th1 commitment.
This possibility is consistent with our finding that antigen-
independent activation of TLR2-/- splenocytes, using cross-
linked anti-TCR antibodies, induced both T-cell proliferation
and IFN- secretion (data not shown). We do believe that
TLR2-/- mice are capable of developing antigen-specific T cells,
and published data report that these mice contain normal
numbers and types of immune cells.16 Taken together, our
data suggest that the absence of TLR2 renders the mice
incapable of responding to the adjuvant activity manifested
by the mycobacteria themselves. This adjuvant activity is
critical for the development of T cells that recognise myco-
bacterial antigens, and for the ability of the host to mount
an effective adaptive immune response. Because TLR2-/-
macrophages fail to secrete critical proinflammatory cyto-
kines in response to mycobacterial infection in vitro, it is
likely that these cells also fail to express critical cytokines
and co-stimulatory molecules in vivo during the course of
infection. Dendritic cell maturation and function may also be
defective in TLR2-/- mice due to the inability of these cells to
respond to mycobacterial TLR2 agonists. Several laboratories
have previously shown that TLR agonists induce dendritic
cell maturation and activation.22-24 Furthermore, those dend-
ritic cells that are incapable of responding to TLR agonists
fail to mature and become functional in vitro.25 Studies are
currently underway in the laboratory to characterise the
immune defects observed in TLR2-/- and TLR4-/- mice. 
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Van der Meer: I enjoyed that very much. Just to go back to
the concept of the Toll-like receptor (TLR) as first line of
response, can you tell us a bit more about the molecular
interaction between bacterial components and TLR? Do
they actually bind, and if so, how?
Fenton: Some of you may have noticed that I tried to stick
to the word ‘agonist’ rather than to the word ‘ligand’. That is
not a mere coincidence. With the exception of Gram-negative
bacterial lipopolysaccharide (LPS) there has really been no
clear biochemical demonstration of any of these molecules
serving as classic ligands and we have little sense of what
the affinity of ligands for these receptors is. In the matter
of LPS, Richard Ulevitch’s lab and a few others have sought
to demonstrate a physical interaction in using cross-linking
approaches. They have been able to show a physical associa-
tion between Gram-negative LPS and TLR4 in the presence
of the coreceptors CD14 and MD2. If you transfect the cell
with an expression plasmid encoding TLR4 in the absence
of the coreceptors CD14 and MD2 you basically have to
throw in milligram amounts of LPS to get an activation. So
from the point of view of ligand-receptor interaction all these
Toll-receptor agonists are very poor ligands by themselves.
They probably operate in the context of a larger receptor
complex that includes coreceptors such as CD14. I think
it is reasonable to assume that there are a variety of co-
receptors that may help TLR2 agonists or TLR9 agonists to
also recognise the receptors and engage a signal. The other
part of this paradigm relates to how strongly the receptor
is engaged and what the kinetics of this interaction are.
Several studies that have been published using FACS analysis
to look at receptor complex interaction have shown that, if
you use FITC-labelled LPS as your classic ligand, you can
demonstrate a rapid and transient interaction between LPS,
TLR4 and CD14. But interestingly, a few seconds or minutes
after this initial interaction and activation the receptor
components seem to move to different places on the cell
and in some cases some of the components are internalised.
Many of you here are familiar with Sam Wright’s work and
the story of LPS internalisation. I think that if you take
this together for LPS it suggests that there is a multireceptor
component that is not assembled and only engaged on the
cell surface for a very short period of time to allow a signal
to be generated. The receptor components then disassemble
and go elsewhere following the activation. There does
not seem to be a strong high-affinity interaction between
TLR proteins and any of their agonists in the absence of
coreceptors.
Hermans: I have a question about the polymorphisms that
are known to occur both in TLR4 and TLR2. In TLR4 there
are amino acid substitutions known to lead to hyporespon-
siveness. But as far as I am aware they do not show much
of a link with the severity of or susceptibility to infectious
diseases.
Fenton: As far as I am aware there is not a strong correlation
in this case between TLR4 mutations and susceptibility
to disease. In experimental models with normal human
volunteers looking at the susceptibility to LPS by inhalation,
David Schwartz has been able to show a correlation between
certain polymorphisms in TLR4 and hyporesponsiveness
of humans to LPS.1 But at least so far there does not seem to
be an increased incidence of disease. The very few studies
that have been published so far looked at the extracellular
domains of the Toll-like receptor proteins. Most of the
work today is focused on the intracellular domains
looking at intracellular signalling. Some new studies in the
Journal of Immunology have shown that the extracellular
domain of TLR4 possesses a hypervariable domain and
most of the polymorphisms seen in different human
populations or amongst different species seem to cluster
in this hypervariable region. It does seem to have an
impact on the ability of TLR4 to recognise LPS or different
forms of LPS as well. So we are beginning to get a sense
of where within the molecule recognition really occurs,
but so far the correlation with disease has been minimal.
Ottenhoff: I have a question about the IL-12. You said that
TLR2 knock-out mice produce normal IL-12 upon BCG
Discussion following lecture by M.J. Fenton
stimulation. In vitro there is little interferon- production.
So my question actually is, what is the mechanism to
explain that?
Fenton: That is a good point. Dr van der Meer said last
night at dinner that we were supposed to expose all of our
Achilles heels to the panel today. So it turns out to be a
very complicated story. You really need to approach it
from three different angles. One is to look at the question
of how purified TLR agonists induce specific responses in
macrophages in vitro. The next would be then to look at
the whole bacterium as well, because those responses are
going to be very different. A great example of this is if
you look at nitric oxide (NO) production induced by
mycobacteria. I am a bit slow maybe in getting to the
answer to your question, but you can add purified LPS for
example as a classic TLR4 agonist and show that you can
activate nitric oxide production and that occurs through
the TLR4 pathway. If you then use live mycobacteria to
induce NO it turns out that in that setting it is a TLR-
independent process that drives the NO production. We
published those results a few years ago. So you have got
to try to keep the two pathways apart. With the data I
showed for IL-12, we have not yet determined whether
the IL-12 production is dependent on TLRs or not in that
setting. It may be in the setting of whole live mycobacteria
that the macrophages do not need TLRs to make IL-12.
Experiments are going on right now in the laboratory to
determine that. Now in vivo you would have expected that
the presence of IL-12 would have correlated with a fine
ability to produce -interferon. So I think that is going to
be the biggest Achilles heel of the data I showed you today,
which are all unpublished and very preliminary, which is
why do we see good IL-12 production and not good -
interferon production? I think the reasons for that can
differ for the two kinds of mice. In the case of the TLR2
knock-out mice, I think we are failing to get -interferon
production because we failed to develop a large panel of
antigen-specific T cells. The T cells are just not there. You
can give them all the IL-12 you want and they will not do
anything with it. The TLR4 knock-out animal is a bigger
mystery because we – presumably – have antigen-specific
T cells there but they are not making -interferon. I
think part of that answer comes from the process of a
Th0 cell maturing into a Th1 cell. So one possibility is
that in the absence of TLR4 we are unable to fully activate
the development of a commitment to the Th1 phenotype.
I should point out that we do not have Th skewing here.
We are not skewing the animals towards Th2. There is
no production of IL-4 and IL-5 in these TLR4 knock-out
animals. We therefore think that there is a defect in Th1
commitment and we are testing that possibility now. The
other issue may be a threshold issue. We have not looked
at IL-18 or at IL-23 as other components of these three
cytokines leading to -interferon production. It may be
that again we have plenty of IL-12 but not sufficient IL-18
and IL-23 to lead to a threshold of -interferon production.
Lastly, in the C3H/HeJ model, where we now have a higher
infective dose and we do see disseminated bacterial growth
when you look at IL-12 levels in the serum of these mice,
you do find in this case that the IL-12 levels in the animal
are lower. I think that under those conditions we are
seeing a correlation and -interferon levels are way down
in these animals as well. So under the right conditions we
can see it. All I can say to answer your question directly is
that the splenocyte assay gives us an answer with regard to
T-cell responses in the dish, but I do not think that it will
really surprise anyone here that that does not necessarily
correlate with what happens in vivo.
Netea: I have two questions. One is going back to the
coreceptors for TLRs. When you mentioned all the TLRs
and the agonists that are known, you did not include
TLR6 and TLR1. They are described as possibly serving as
coreceptors. Do you think that there are two classes of
TLRs? TRLs which are really signalling and TLRs which
are coreceptors? That is my first question, and a second
one relates to the Toll reacting to Spätzle, an endogenous
substance in Drosophila. In humans most of the data are
done in the context of pathogens and we get more or less
the same signals as in the context of IL-1 stimulation. My
question is, why do you think that we also need an IL-1
system? We do have more or less the same intracellular
signalling going through TLRs. Do you think that we in
fact developed a kind of intention to amplify our TLR
system by using IL-1?
Fenton: The TLR2 and coreceptor question is of course an
important one. Those of you who are familiar enough
with the data will probably agree that TLR2 probably does
not work alone. TLR proteins probably function as
dimers. In the case of TLR2 it probably functions only as
a heterodimer in association with either TLR1 or TLR6.
We do not have any data so far to answer the question
whether TLR2-dependent responses also utilise TLR6 vs
TLR1, so I cannot answer that question. In terms of
whether they are coreceptors or actually contribute differently
to the signalling in the intracellular responses, it is quite
likely that they will. I think that if you look at responses
mediated through TLR2.1 vs 2.6 you are likely to find
some differences. Most people who have looked at TLR-
dependent responses have focused on a similar set of
cellular responses such as IL-6 or TNF production, IL-1
production. Those seem to be shared in common with all
of the TLR receptors. It is only when you begin looking at
different responses that you start to see differences: for
example our findings that TLR4 engagement leads to
type-1 interferon production, but engagement of TLR2
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does not. I think you are likely to see differences between
TLR2.6 and TLR2.1, but the data have not been published
in that regard. It is also – just before I leave the topic of
coreceptors – quite likely that non-TLR coreceptors are
going to be involved as well. I think there is indirect evidence
to support complement receptors as being TLR coreceptors,
perhaps the macrophage mannose receptor or the scavenger
receptor, maybe even certain Fc receptors as well. 
To answer your second question, I think it ties in a bit
to what I have just said, which is that there are certain
common responses that seem to occur when you activate
all of these receptors, not only all of the TLR receptors but
also the IL-1 and IL-18 receptors. But clearly the functional
responses of the cells are different. You can induce for
example apoptosis in some cells triggered through TLR4,
TLR2, but certainly not in cells stimulated through IL-1 or
IL-18. So as usual the devil is in the details. There are
certain responses that seem to be Toll dependent and
certain responses that are specific for Tolls and not for
IL-1 or IL-18 receptors. So what does that mean in the big
picture of the biology? I think that like the IL-1 and IL-18
receptors, Toll receptors play an important role in the
inflammatory response. The inflammatory response as a
result of a pathogen invasion, but perhaps an inflammatory
response mediated by endogenous factors as well. There
certainly is an amplification loop going on here. IL-1 and
IL-18 production is certainly going to be important in
maintaining the inflammatory response and the duration
of the response, and there is also the likely possibility that
endogenous factors are being made that feed back into
the Toll receptors themselves.
You pointed out the ligand for the Drosophila Toll, the
Spätzle protein. Spätzle is produced and cleaved and
feeds back into the Toll itself, but just as in the mammalian
Toll agonist, no-one has actually demonstrated Spätzle
binds as a ligand to Toll. It is all indirect evidence that
supports that hypothesis. There are some studies suggesting
that mammalian proteins can feed back into Toll receptors,
heat-shock proteins being an important example. 
Cells that are damaged in the course of bacterial invasion
may release these heat-shock proteins, they may be an
endogenous danger signal as well. There is no evidence
that these proteins can recognise IL-1 or IL-18 receptors.
So I think we can draw a series of circles some of which
will overlap. I think the IL-1 and IL-18 receptors and the
Toll receptors play similar roles in the development and
maintenance of inflammation. But I think they also play
highly specific roles depending on the type of pathogen
and the type of response and whether it is an organism
possessing TLR4 antigens or not. I think it is almost as if
we can say that the innate immune response is adaptive
in that it can recognise a variety of different motives
through this large variety of different TLR proteins that
are available.
Verbrugh: I have three more discussants who want to ask
a question.
Appelmelk: What is your explanation that a knock-out in
TLR2 completely blocks all T-cell development? I can
understand it for lipoarabinomannan within the CD1
environment but not for Toll-independent proteins in the
CD4 environment.
Fenton: Hopefully it will be the simple answer that in the
absence of TLR2 you fail to get the expression of a basic
set of cytokines and costimulatory molecules that are
necessary to clonally activate T-cell populations. Let’s hope
it is just as simple as that. We have tested the antigen
presentation function in the TLR2-deficient cells and
antigen presentation appears normal. So we think it is a
defect in either costimulus or cytokines.
Kuijpers: My question is related to the fact that a moderate
dose of BCG could be coped with in the TLR4 knock-out
mice. Is it due to the fact that there is an increased level
of other cytokines available (thinking about TNF), or has
that been dealt with experimentally?
Fenton: We have only looked at a few cytokines in that
model. The circulating TNF levels appeared to be normal
in those animals. So far, we have just seen the deficiency
in -interferon and IL-12.
McAdam: I have a question similar to the last one. Did
you see any granulomatosis inflammation in the TLR2-
deficient mice?
Fenton: We have not looked into the model long enough
to test that out. The other problem is, we cannot do that
with the BCG model, because the mice clear the infection,
even the TLR2-deficient mice at that initial inoculum of
bacteria that we would use. So where I would normally
want to look at granuloma formation 40 days after infection
even the TLR2 knock-out mice have cleared the infection
by then. In the case of using higher inocula, we see a
disseminated infection, as you saw on the one slide. We
did not see anything that looked like a true granuloma.
We did not see any organisation in either the TLR4 or the
TLR2 knock-out mice. So I did not want to jump to any
quick conclusions, but from looking at the initial data we
have, there seems to be very poor granuloma formation.
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I N T R O D U C T I O N
Human genomics and the rapidly growing insight into
the host inflammatory response explain the increasing
interest in infectious disease genetics over the last five to
ten years. Host genetic factors are major determinants of
susceptibility to infectious diseases in humans. Candidate
gene studies by association and human genome-wide
analysis have been used to identify susceptibility and
resistance genes in infectious diseases. However, a single
gene defect has rarely been directly related to a devastating
diseases, such as interferon-gamma receptor (IFNR) or
interleukin-12 receptor (IL-12R) mutations leading to
severe or fatal infections with mycobacterial strains.
In clinical terms, gene polymorphisms of the host immune
defence factors appear to have a much broader role and
contribution to health and disease. These genetic
variants, which modify the regulation or function of the
mediators, have been associated with susceptibility to
and/or outcome of severe sepsis and septic shock. All steps
of the host response to bacteria may be affected by genetic
factors. For example, Fc receptors (FcRs), Toll-like
receptors (TLRs), CD14 and mannose-binding lectin
(MBL) mutations have all been shown to modify the host
detection of pathogens leading to pneumococcal infections,
Gram-negative bacteria septic shock, and meningococcal
disease. Polymorphisms of cytokine genes (TNF-, IL-1
receptor antagonist (IL-1RA), IL-10, etc.) have been reported
to influence the level of secreted mediators and to unbalance
the inflammatory cascade. Coagulation response to sepsis
may also be affected by gene variants such as the plasmino-
gen activator inhibitor 1 (PAI-1) common functional
polymorphism that increases the risk of death from
meningococcal infection. 
In this paper we will largely focus on the contribution of
FcRs in infectious disease.
P H A G O C Y T E S
The expression of FcRs is limited to cells of the haemato-
poietic lineage (table 1). The consequence of IgG binding
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Human Fc receptor polymorphisms in 
relation to bacterial infection 
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A B S T R A C T
Human IgG receptors are very heterogeneous. Currently there are three Fc gamma receptor classes specifying at least
12 receptor isoforms to be distinguished. On top of this complexity, Fc gamma receptors (FcRs) differ between different
individuals. Polymorphisms have been identified for two FcR classes, representing allelic variation of the FcRIIa
(CD32), FcRIIIa and FcRIIIb (CD16). The FcRIIa polymorphisms are now considered to be a heritable risk factor for
infectious diseases and some manifestations of autoimmune disorders. A relevant role of the IIIb polymorphism in
infectious disease has been suggested, though less convincingly. Detailed analysis of the exact contribution of each of these
polymorphisms in relation to previously implicated risk factors for infectious or immunological disease should unravel
the pathophysiological contribution of FcR polymorphisms in the wide variety of factors now being investigated.
The information obtained about the multiple genes that impact inflammatory responses of the host – and most likely in
reaction to exogenous triggers and pathogens – is becoming overwhelming. The rapid development of molecular techniques
makes it possible to determine the incidence of all these individual genetic polymorphisms. Although its relevance will
be more difficult to ascertain, the information on all the different genes and their allelic variations involved in the host
immune response will be very important for our understanding of infectious disease in modern times. 
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to these receptors varies among the cells in relation to
their primary function. In the case of infectious disease,
it is clear that the phagocytes have the greatest impact on
clearance and elimination of bacterial and fungal pathogens,
both from tissues and the circulation. The professional
phagocytes to be distinguished are mainly formed of
neutrophilic granulocytes, monocytes and monocyte-derived
tissue macrophages. Neutrophils constitute the major type
of leucocytes in peripheral blood, with counts ranging
from 40 to 70% under normal conditions. Neutrophils
contain numerous proteases and other proteins in their
granules and can produce – when activated – a large
quantity of toxic oxygen metabolites through the NADPH
oxidase activity to kill tissue-invading pathogens.1,2
Neutrophils protect our bodies against so-called extracellular
bacterial and fungal micro-organisms, whereas the
macrophages are particularly involved in and equipped
for the killing of intracellular pathogens. Neutrophils
have a high turnover rate. Once these cells have egressed
from the bone marrow, their half-life in the peripheral
circulation is about six to eight hours before they leave
rather randomly into the extravascular tissue where the
neutrophils roam for another 24 hours. In the case of
inflammation, circulating neutrophils sense the site of
infection, rapidly extravasate and crawl in large quantities
towards the invading micro-organisms to ingest and kill
them.2-4 During an infection monocytes follow only later
to perform the role of scavenging cell, to engulf the
remaining apoptotic neutrophils, and to prepare the local
environment for recovery from the tissue damage inflicted
during the first wave of neutrophil-mediated inflammation.
Macrophages are tissue-dwelling cells derived from mono-
cytes with an estimated half-life of three to four months.
Macrophages can be found in any organ or tissue, though
in different forms and endowed with different functions.
These cells are well situated and actively involved in liver
and spleen clearing the blood compartment from aged cells,
oxidatively damaged material, as well as filtering out any
bacterial pathogen that escaped the defence system of
skin or mucosal lining, including the destructive power of
tissue-infiltrated neutrophils. Thus, for proper functioning
of this first line of defence by phagocytes, a number of
prerequisites have to be fulfilled. 
P H A G O C Y T O S I S  A N D  M I C R O B I C I D A L
A C T I V I T Y
Phagocytes operate in concert with antibodies and comple-
ment factors, so-called opsonins. Micro-organisms covered
with these opsonins are bound through specific receptors
for these opsonins on the plasma membrane (table 1).
Antibodies bind with their Fab regions to microbial anti-
gens. In this way, the Fc regions of these antibodies are
closely packed together. This spatial arrangement enhances
complement activation, thus leading to binding of C3b
and C3bi to the micro-organisms and subsequent binding
of the microbes to the complement receptor type 1 (CR1)
Table 1
Opsonin receptors on leucocytes
RECEPTOR CD GENE EXPRESSION
Fc receptors
FcR-I CD64 FCGRIA Monocytes, macrophages, IFN-- or G-CSF-stimulated neutrophils
FCGRIB -
FCGRIC -
FcR-II CD32 FCGRIIA Neutrophils, eosinophils, basophils, Monocytes, macrophages
Platelets
FCGRIIB B lymphocytes
Macrophages (neutrophils?)
FCGIIC NK cells
FcR-III CD16 FCGRIIIA Macrophages, NK cells
FCGRIIIB Neutrophils
FcRn FCRN Syncytiotrophoblasts, intestinal epithelial cells
FcR CD89 FCAR Neutrophils, monocytes, mesangium cells
Complement receptors
CR1 CD35 CR1 Erythrocytes, granulocytes, monocytes
CR2 CD21 CR2 B lymphocytes
CR3 CD11b/CD18 CD11B and INTG2 Neutrophils, eosinophils, basophils, monocytes, macrophages, NK cells
CR4 CD11c/CD18 CD11C and INTG2 Monocytes, macrophages, neutrophils, eosinophils, basophils
C1qR? CD91? Monocytes, neutrophils, eosinophils, endothelial cells?
and complement receptor type 3 (CR3) respectively. On the
other hand, the proximity of the antibody Fc regions also
promotes direct binding of the opsonised micro-organisms
to the Fc receptors on the phagocytes.5
Two types of Fc receptors are present on neutrophils:
FcRIIa and FcRIIIb. Only after long-term activation of
neutrophils by interferons or growth factors is a third Fc
receptor expressed, i.e. the FcRI, which binds monomeric
IgG with high affinity (table 2). In contrast, the constitutively
expressed FcRIIa and FcRIIIb bind monomeric IgG
only with low avidity, but can efficiently bind immune
complexes containing multiple IgG molecules. A poly-
morphism in FcRRIIa defines the intrinsic ability to
recognise all four IgG subclasses or not. IgG2 antibodies,
often formed as the most predominant IgG subclass of
antibodies against the microbial carbohydrate structures,
only react with the so-called L131 type of FcRIIa (with a
leucine at amino acid position 131). As will be discussed
later, it is generally assumed that individuals with this
isotype are better protected against infections with certain
micro-organisms than individuals with the R131 type of
FcRIIa (arginine at position 131). 
FcRIII has two variants, a transmembrane form
(FcRIIIa) expressed on macrophages and natural killer
cells, and a neutrophil-specific form (FcRIIIb) linked to
the plasma membrane by a lipid anchor, which allows very
rapid redistribution and early localisation of opsonised
material. Although there is a polymorphic site in the
FcRIIIb on neutrophils (NA1/NA2 depending on dif-
ferences in glycosylation), its effect on clinical outcome is
as yet not as clear as in the case of the FcRIIa. In contrast
to all other transmembrane FcR members, the FcRIIIb
on neutrophils can be rapidly shed from the membrane
during functional activation or during the process of
programmed cell death (apoptosis) in the tissues. The
presence of soluble FcRIIIb plasma in combination with
its relatively long half-life renders this molecule a prime
candidate for the estimation of total neutrophil mass.6
Monocytes express the FcRI and FcRIIa whereas
macrophages show FcRI, reduced FcRIIa and a high
level of FcRIIIa. FcRIIIa has two polymorphic sites of
which the FcRIIIa-158V/F allotypes show some functional
influence on the avidity of IgG subclass binding, of IgG4
in particular.7 The FcRIIIa-V/F158 allelic variation possibly
influences autoimmune disease in its presentation, course
and outcome. Even in one type of disease, the published
data of groups of patients with various racial backgrounds
are contradictory or at best inconclusive.8,9
Studies on the inhibitory action of FcRIIb were largely
limited to B-cell functions. With the current insight
from experimental FcRIIb-knockout models,10,11 its
expression on macrophages (and other phagocytes) and
– as a consequence – its impact on the outcome in 
inflammatory responses as well as on the efficacy of intra-
venous immunoglobulin infusions in an experimental
model for immune thrombocytopenia12 has been demon-
strated. The precise working mechanism of the disease-
mitigating role of FcRIIb should be elucidated in the
near future, also in human disease.
M I C R O B I C I D A L  A C T I V I T Y
Binding of opsonised material to surface receptors leads
to concentration of such receptors around the area of
contact. Subsequently, the cell extends pseudopods that
engulf the particle. By consecutive receptor binding, these
pseudopods fit tightly around the particle and finally fuse
with each other to form a closed membrane vesicle
(phagosome) around the particle, within the phagocyte.
Neutrophils may overeat themselves in infected areas and
die of congestion. Macroscopically, this is manifested as
pus formation. Apart from phagocytosis, receptor binding
may also start two other processes, i.e. the generation of
reactive oxygen compounds and the release of granule
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Table 2
Function of Fc and complement receptors on phagocytes
EFFECT
NOMENCLATURE EXPRESSION LIGAND PHAGOCYTOSIS MEDIATOR RELEASE CYTOTOXICITY
FcRI (CD64) Constitutive*/long-term IgG + + +
activation**
FcRII (CD32) Constitutive, stable expression IgG + + +
FcRIII (CD16) Shed upon activation IgG - + +
FcR (CD89) Constitutive, stable expression IgA + ? ?
CR1 (CD35) Upregulated upon activation C4b/C3b + + +
CR3 (CD11b/18) Upregulated upon activation C3bi + + +
CR4 (CD11c/18) Upregulated upon activation C3bi/C3dg + + ?
* Constitutive expression on monocytes and macrophages, ** activation-dependent expression on neutrophils.
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contents. Both reactions are localised events in that they
are restricted to the release of microbicidal products into
the phagosome. However, the secretion of these products
begins before the phagosome is closed, and some of the
oxygen compounds and granule enzymes may thus escape
into the extracellular environment of the neutrophils.
Moreover, neutrophils adhering to opsonised material
that is too large to be ingested (e.g. immune complexes
deposited along basement membranes) may secrete these
products in large quantities into the extracellular space.
Under such conditions, macrophages can fuse with each
other forming large tissue multinuclear histiocytes as an
important cell type, as is often present in granulomata.
Degranulation does not occur in resting neutrophils,
monocytes, or macrophages. During phagocytosis or
adherence of neutrophils to large substrates, intracellular
signalling events induce the fusion of granules with
the plasma membrane. Neutrophils contain at least two
different types of granule; most likely the same holds true
for monocytes. In macrophages, the granular content is less
apparent. The azurophil granules resemble the lysosomes
in other cell types in that they contain acid hydrolases,
with a low pH optimum. Moreover, these granules also
contain myeloperoxidase (MPO) and a number of serine
proteinases (elastase, cathepsin G, proteinase 3). Further,
the azurophil granules also contain large numbers of
defensins, small peptides with a broad range of bactericidal
activity, and bactericidal permeability-increasing protein
(BPI), a very potent antibiotic against Gram-negative bacteria.
Lysozyme, an enzyme that hydrolyses certain peptidoglycans
of Gram-positive bacteria, is present in the azurophil as
well as in the specific granules of the phagocytes. Proteins
specifically found in the specific granules comprise 
lactoferrin, an iron-binding and therefore bacteriostatic
protein, vitamin B12-binding protein, and the metallo-
proteinases collagenase and gelatinase. Neutrophils possess
far more granules than monocytes or macrophages.
Finally, neutrophils also contain so-called secretory vesicles,
which actively exchange their membrane-bound receptors
and enzymes with the plasma membrane. In contrast,
macrophages have a vesicular system of endosomal
trafficking – although not as elaborate as the dendritic
cells – for exchange and presentation of antigen as an
antigen-presenting cell, which is absent in neutrophils. 
Simultaneous with degranulation, a membrane-bound
oxidase enzyme complex located in the membrane of
secretory vesicles and specific granules can be activated to
generate reactive oxygen compounds needed in the killing
process. This NADPH oxidase complex is composed of
several subunits in the plasma membrane (cytochrome
b558  and  subunit: p22-phox and gp91-phox) and a
number of activity-regulating proteins in the cytoplasm (e.g.
p47-phox, p67-phox). Phagocytes at rest do not generate
superoxide. Only after opsonin/ligand binding to cell
surface receptors is the active NADPH oxidase assembled
to generate superoxide in phagocytes. Superoxide spontan-
eously dismutates into hydrogen peroxide that may then
react with chloride ions to form hypochlorous acid (HOCl).
This reaction is catalysed by MPO, when released into the
phagosome or the extracellular space. HOCl is very toxic
for a broad range of micro-organisms but is rather short-
lived. However, it can react with primary and secondary
amines, and thus give rise to N-chloramines, some of
which are very stable microbicidal agents. Under normal
phagocytosing conditions, neutrophils convert more than
75% of their superoxide into hypochlorous acid and
N-chloramines, and thus create a highly toxic environment
within the phagosomes and in the cell surroundings.
M E A N I N G  O F  F C  R  P O L Y M O R P H I S M S
I N  I N F L E C T I O N
Since the FcRIIa (CD32) is the sole IgG FcR capable of
interacting with human IgG2, the main IgG subclass of
bacterial capsular polysaccharides, most studies on infec-
tions with encapsulated bacteria have focused on the FcR
allotypes: i.e. FcRIIa-R131 and IIa-H131. 
The retrospective study by Bredius et al. first showed in a
small cohort of 25 children with prior fulminant meningo-
coccal septic shock that almost half of the children were
homozygous for FcRIIA-R/R131, the poor IgG2-binding
allotype. This allele frequency was significantly different
from its frequency in a healthy white population (44% vs
23%, p=0.03). The relevance of this finding was further
supported by the fact that neutrophils with the FcRIIa-
R/R131 allotype phagocytised N. meningitidis opsonised
with polyclonal IgG2 antibodies less effectively than did
IIa-H/H131 neutrophils.13 Another Dutch group had
determined the FcRIIa and FcRIIIb phenotypes of 48
children with recurrent bacterial respiratory tract infections.
FcRIIa-H/H131 was less than half that observed in 123
healthy adults (p=0.01). IgG2 responses were low in 25
out of 48 patients after immunisation with pneumococcal
vaccine. The authors’ conclusion was that FcRIIa poly-
morphisms contribute to increased susceptibility to infec-
tions with encapsulated bacteria in a childhood population
with low IgG2 anti-carbohydrate antibodies.14
Similar variation in allele frequency was studied in small
groups of patients with additional opsonisation defects in the
complement system. The distribution of FcRIIa and IIIb
allotypes in 15 individuals with a deficiency in one of the
late complement components (LCCD) and in 15 properdin-
deficient patients with/without previous meningococcal
disease was analysed. The combination of FcRIIa-R/R131
with FcRIIIb-NA2/NA2 allotypes was associated with
previous meningococcal disease (OR=13.9, p=0.036). No
such relation was observed in the properdin-deficient
patients.15 Another study in LCCD patients had previously
shown that the distribution of FcRIIa genotypes and
disease demonstrated an apparently clear age effect. The
R/R131, R/H131, and H/H131 genotype distribution was
0.14:0.29:0.57 for patients with their first disease episode
<10 years of age, as compared with the distribution of
0.21:0.64:0.14 for those with their first episode >10 years
(OR=8.0, p<0.05). Meningococcal disease had a more severe
course in four out of 31 episodes in patients with the R/R131
or R/H131 allotypes, in contrast to one out of 18 in patients
with H/H131 (OR=14.2, p<0.01). Thus, CD32-mediated
phagocytosis may restrict the severity of meningococcal
disease in LCCD patients with the H/H131 genotype.16
In a rather heterogeneous cohort of paediatric and adult
HIV-positive individuals, skewing in FcRIIa R/H131 allele
frequency was not observed in relation to pneumococcal
invasive disease.17 In 60 black children with sickle-cell
anaemia (SCA) and well-documented bacterial infections,
the R/H131 genotype distribution in the 51 individuals with
a history of Streptococcus pneumoniae infection was also not
statistically significantly different from that of the control
population. In contrast, however, the H/H131 genotype was
unexpectedly overrepresented in the 11 individuals with a
well-documented history of Haemophilus influenzae type-b
infection (64% H/H131, 27% H/R131, 9% R/R131, p=0.002)
when compared with ethnically matched controls (14%
H/H131, 60% H/R131, 26% R/R131).18
A case-control study on the risk and outcome of meningococ-
cal disease in 130 patients with microbiologically proven
meningococcal disease and 260 asymptomatic sex-matched
controls indicated a lack of skewing in allele distributions
of FcRIIA allotypes.19 In comparison with meningococcal
meningitis, however, both the fulminant meningococcal
disease (OR=3.9, 95% CI 1.0 to 16, p=0.04) and sepsis
without meningitis (OR=3.0, 95% CI 1.4 to 7.8, p=0.004)
were associated more commonly with the FcRIIA-R/R131
allotype than to those with meningococcal meningitis. Of
the 42 patients with the R/R131 allotype, 31 (74%) had an
adverse prognostic score, compared with 7% (4 of 59) of
those with the R/H131 allotype and 3% (1 of 29) of those
with the H/H131 allotype (p<0.0001). 
Thus, the FcRIIA-R/R131 allotype may not act as a strict
susceptibility gene but – instead – a severity marker,
associated with the more severe forms of meningococcal
disease. This remains to be confirmed for other encapsulated
pathogens. 
C O N C L U D I N G  R E M A R K S
The meaning of polymorphic variations in the genes for
the FcRIIa, FcRIIIa and FcRIIIb is far from clear at the
moment. Most studies describe small and heterogeneous
groups, and may at best tell us something about differences
within a certain cohort. Then, the polymorphisms indeed
show their most characteristic features, such as an age
effect, a difference in outcome and symptomatology,
and – presumably – a different treatment effect. The role
of these polymorphisms seen as a separate issue in the
host defence response indicates a subtle impact, more
interesting from the perspective of pathophysiology than
for the therapeutic options to date. This may change rapidly
as soon as monoclonal antibodies enter the clinics for the
reasons outlined above.
In the first phase of inflammatory responses or other forms
of stress, chemotaxins such as C5a, lipid mediators, and
so-called chemokines are produced. The secretion of
chemokines can be firmly induced by the proinflammatory
cytokines derived from tissue macrophage and T cells such
as TNF-, IL-1, and IFN-, or by bacterial products such
as lipopolysaccharide (LPS) from Gram-negative bacteria,
peptidoglycans from Gram-positive bacteria, or lipoarabino-
mannans from mycobacteria.
The process of recruitment is complex and still incompletely
understood. Once recruited, the phagocytes – and neutrophils
foremost – have a wide range of toxic mechanisms to
fight any invading micro-organism, as described. These
mechanisms are strongly regulated and delicately controlled
because an over-excessive or premature induction of the
toxic activities may result in the inactivation of protease
inhibitors and activation of several cascades of activating
substances (e.g. coagulation and fibrinolysis, the comple-
ment system). As a consequence, bacteraemia may progress
to septic shock and disseminated intravascular coagulation,
a community-acquired pneumonia may develop into acute
or adult respiratory distress syndrome, and hypoxia/
reperfusion injury can lead to fatal circulatory collapse. 
In many of these early steps of inflammation, molecules are
involved in which allelic variation has been characterised,
often in the coding or promotor regions, as well as in the
nontranscribed intronic sequences or 3’-regions. Their
meaning in biological and – as a consequence – in clinical
terms remains to be clarified. The FcR allotypic variation
is only a minute factor within the complex sequence of
reactions in the host immune reaction to an invading
pathogen.
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Discussion following lecture by T.W. Kuijpers
Turner cooperated for his study of mannose-binding lectin
(MBL). Once again, by checking all the known genotypic
or allelic variation in these children, there is no clear-cut
skewing in any of the polymorphisms presently known, not
even for the MBL mutations. You can count the number of
infections that these 200 children have, but indeed once
again this is an anamnestic response by parents, and thus
prone to recall bias. The only way to find out the truth is
in a proper prospective study, preferably not in a tertiary
centre, in order to have the broadest population possible.
But what surprised us was that even the MBL mutations
were definitely not skewed to a particular mutation as
compared to controls.
Turner: I would not disagree with that. I think most of the
studies on MBL today should have been done in centres
where there have been tertiary referral hospitals collecting
the samples. That is one of the reasons why we are doing
a large study in the West of England – it is called ALS-
PAC, the Avon Longitudinal Study of Pregnancy And
De Groot: I appreciate your remark about susceptibility and
severity at the end of your presentation, which brings me
to my question. It also relates to the first speaker, Dr Turner,
who said, as I understand, that in the study on Mycoplasma
pneumoniae infection there was a question of susceptibility.
I fully agree with your statement that these molecules of
innate immunity are more likely related to the severity of
infectious diseases than to susceptibility. But if that is the
case, could you comment on the type of studies that we
have done so far, which are skewed, because most of them
deal with retrospectively acquired material in highly selected
populations from university settings and they are not
prospectively done, i.e. they are not population-based. Can
you give us your perspective on this? Maybe Dr Turner
has a response to this question?
Kuijpers: First of all, we are now trying to do all these studies
in a larger cohort of about 200 patients with recurrent
respiratory tract infections more or less similar to the
study already mentioned by Summerfield in which Dr
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Childhood – which Professor Jean Golding set up in the
early 1990s to follow 14,000 pregnancies, and we are just
completing a study of 8000 children to see what correlates
we can find for disease associations in those children.
That is a true prospective study. These sorts of studies are
desperately needed for these innate immune markers.
Van der Meer: Just to get back to the point of the Mycoplasma
infection as a complication in hypogammaglobulinaemic
patients, the question there as well is whether it is a severity
or a susceptibility marker. 
Turner: You are right, it was mainly infection due to M.
hominis, and the patient cohort was a mixture of common
variable immunodeficiency and also some X-linked agamma-
globulinaemia patients who had started off as a study of
common variable immunodeficiency – the Mycoplasma
association was discovered as an incidental part of that.
So we then enlarged the cohort for Mycoplasma.
Kuijpers: I want to point out the study already mentioned
by Peter Garred in cystic fibrosis. Considering a drop of
eight years in lifespan, it is crucial when you are also
MBL-deficient. Then you may think about prospective
treatment options being available nowadays for those CF
patients who are MBL-deficient. But that can only be done
in a proper setting with a multicentre study. Without such
collaboration we probably remain stuck with the question,
is it susceptibility or severity? A severity marker is already
important, but only in certain cohorts.
Appelmelk: Dr Kuijpers, first can you explain to me, when you
have an allele in a low-affinity receptor causing inactivity,
why doesn’t the high-affinity receptor take over? It sounds
as though there is some redundancy in the system. So how
does that work?
Kuijpers: I think you are completely right in mentioning
this. Of course, all comes down to the initial thought and
idea that these polymorphic sites in case of IgG2 opsonising
mechanisms were of importance because there was a strict
difference in whether you had the one or the other genotype,
FcRIIa. Of course, the other studies were a kind of follow-
up to that, first of all trying to confirm their ideas, and
then suddenly these genotypes for the IIIa were showing
different expression patterns and especially so in the auto-
immune diseases. If a macrophage expresses so many
Fc-receptors, having the opportunity to bind IgG-laden
material, it is indeed questionable why it would not be
taken over by other Fc receptors. I think a lot of the work
in autoimmune diseases in fact confirms the genotype
skewing. There are more molecules involved in immune
reactivity as such. Think about the IL-6 or proteins related
to apoptosis. Nobody knows in fact. This might simply be
a way to look at something different in that particular
genetic locus, not meaning that it is that particular receptor
as such.
McAdam: Are these same receptors expressed on a placenta
to facilitate the passage of immunoglobulin across the
placenta? Would it be useful to look at babies with neonatal
infections?
Kuijpers: The only receptor believed to be important in the
transport of IgG from the mother to the child is thought
to be the FcRN, so the neonatal receptor, which shows
homology to the HLA class-I molecules. This is not even
related to the FcRI, II or III. So it is a very different
mechanism. There is, as far as I know, no information about
allelic variation in that receptor. Of course, I just mentioned
the polymorphic sites in the FcRIIb: they might be another
thing to study, and especially that it is not in the extracellular
part, where it may have an effect on the function of the
other receptors. That is of course something that may or
may not affect the outcome of an inflammatory reaction.
But once again, I wonder whether that would tell us very
much about susceptibility as such.
Van Agtmael: I would like to ask you a question from a
clinical point of view. In March 2001 there was a study in
Cochrane Review on the use of intravenous immunoglobulins
(IVIG) for sepsis and septic shock and it showed a moderate
effect.1 It would be interesting to look at this group of
patients to find factors in those patients who would benefit
from the intravenous immunoglobulins. Do you think that
it would be useful to look at the Fc polymorphisms in this
broad group of patients with sepsis and to identify those
who might benefit from the IVIG?
Kuijpers: Well, it would not be the first molecule I would
look at, although potentially IVIG may be beneficial. I
think it will be very hard to see in which patients they are
effective. Of course, I am talking very much as a paediat-
rician seeing a lot of meningococcal infections – that is a
very homogeneous population. But when you are practising
internal medicine, there is a huge variation. There are so
many parameters that you have to exclude or include to
come up with a firm idea about which group is definitely
helped by IVIG. The follow-up of those patients studied is
difficult. Did they show a normal humoral response etc?
All that crucial information is completely lacking in these
cohorts. So I don’t know.
De Groot: A small remark on the question concerning the
neonatal infection, which brought me back to the presen-
tation by Dr Turner in the beginning, where he said that
surfactants may play a role as part of innate immunity.
There is data to show that mutations in the genes for
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surfactants A and D are associated with an increased risk
of chronic recurrent lower respiratory tract infection. It is
all very preliminary, and that actually brings me to my
question. I will turn the gun onto myself immediately after
I have said this because so far all these studies – if you have
read Kimman’s nice book – have been done on associations
between single-gene polymorphisms and diseases. You
have already said so, but knowing the literature for instance
on leucocytes or chronic granulomatous disease (CGD),
even in a clear-cut serious mutation disease as CGD there
is a tremendous variability in the expression of the disease.
This varies from patients who do not become ill at all to
those who are very seriously ill with many in between. The
way we study these diseases as clinicians is at this point
in time very simplistic. We try to take one gene mutation
and apply it to a population and look for an association,
whereas it might very well be possible that there are a
hundred genes involved and that the effects of twenty
genes are upregulating severity and there are thirty down-
regulating it.
Verbrugh: I have to intervene as Chairman, because we
have a time problem here. Could you answer that briefly,
because we would like to have two more comments from
speakers before we go on to the next topic?
Kuijpers: This is one of the main points set out by the Dutch
Society for Science, that you have to enter this field by
doing gene arrays and snip arrays, and that may not even
bring a clear answer to your question, because if you have
twenty different genes or snips being characterised in a
certain cohort of patients you come up with the same
question. You have then characterised only a limited
number of these snips. You may be more susceptible,
but then also of course it is a matter of meeting the agent
that can potentially affect you.
Kimman: Are Fc-receptors involved in the response to
vaccinations, and has anybody looked for associations
between response to vaccination and Fc-receptor poly-
morphisms?
Kuijpers: I would say yes, most likely, but whether somebody
has studied that, I am not aware of that.
Van Furth: Just in emulation of the discussion with Van
Agtmael and you, Dr Kuijpers, is there a difference between
persons regarding the turnover of IgG, given intravenously
or just autologous? Have these studies been done?
Kuijpers: I don’t think anybody has done that in a detailed
fashion, and the only thing I could say is that of course
the turnover of IgG very much relates to the FcRN effect.
So I think that a different receptor is involved in rescuing
IgG from being cleared and broken down.
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coagulation and multiple organ failure develop. For an
extensive review of the pathophysiology we refer to previous
reports.1,2
The broad range of clinical presentations of N. meningitidis
infections raises the question why some patients show
hardly any clinical symptoms while others die within several
hours of onset of symptoms. Variations in host genetic
factors are known to contribute to these differences. Genetic
polymorphisms are relatively stable in the human population.
Single-nucleotide polymorphisms (SNPs) are distributed
throughout the human genome at an estimated overall
frequency of one in every 2 kb.3 It has been shown that these
polymorphisms may affect susceptibility to and severity and
outcome of infectious disease. This review focuses on the
current knowledge of genetic variability in the susceptibility
to and severity of meningococcal infections (table 1).
I N N A T E  I M M U N I T Y
TLR
The innate immunity plays an important role in the initial
recognition of invading pathogens. This recognition was,
until recently, believed to be nonspecific. However, elucida-
tion of the function of Toll-like receptors (TLR) has shown
I N T R O D U C T I O N
Despite ongoing improvements in the treatment of infections
by Neisseria meningitidis the mortality rates in patients with
invasive disease are still very high, ranging from 4 to 40%.
This is a reflection of the different clinical presentations
of infection. The disease spectrum varies from meningitis
to sepsis and septic shock. The first entity has a mortality
rate of 4 to 6%, while in septic shock mortality rates up to
40% have been reported. The observation that septic shock
can develop within several hours of onset of meningococcal
invasive disease implies a major role for the innate immunity
in host defence. Meningococcal lipopolysaccharide (LPS)
is one of the major factors to induce the host response
during bacterial invasion. This response is complex and
involves the activation of three major host response systems
(figure 1). The first is the complement pathway that apart
from contribution to phagocytosis of the bacteria also func-
tions as an inducer for the inflammatory reaction through
C3a and C5a. The second system is the inflammatory
reaction mediated by different chemokines and cytokines
among which TNF- and IL-1 play a central role. The third
cascade is activation of the coagulation and fibrinolysis,
which result in a prothrombotic stage. Activation of the
host response in patients with sepsis results in a sudden
onset of fever and a petechial or purpuric rash followed by
hypotension. In patients with septic shock, disseminated
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A B S T R A C T
The clinical presentation of infections by Neisseria meningitidis is highly diverse. Some patients with invasive meningococcal
infections develop meningitis, while others present with sepsis or even septic shock. Three major host defence systems
are activated after transepithelial passage and invasion of the bacteria into the bloodstream. These include the complement
pathway, the inflammatory response by cytokines and chemokines, and the coagulation and fibrinolysis pathway. These
three systems are mutually dependent. Genetic polymorphisms among components of these pathways (co)regulate the
susceptibility, severity and outcome of meningococcal disease. In this paper the current knowledge of polymorphisms
which are known to be associated with susceptibility to and severity of meningococcal infection is reviewed.
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otherwise. TLRs sense different microbial molecules,
covering a range of pathogens that cause infections in the
host. TLR4, for example, recognises bacterial LPS. C3H/HeJ
mice, having a point mutation in tlr4 that abolishes LPS
responses, are hyporesponsive to Gram-negative infections.4,5
The common Asp299Gly polymorphism in TLR4 alters the
extracellular domain of the receptor. Airway epithelial cells
of patients carrying this polymorphism are hyporesponsive
to LPS. However, no association has been found between
the Asp299Gly polymorphism and the susceptibility to or
severity of meningococcal infection.6 Smirnova et al. have
found an excess of rare amino acid polymorphisms in TLR4
of which the clinical relevance has not yet been studied.7
TLR2 recognises other bacterial components, such as
lipopeptides and peptidoglycan.4 Until now the relation
between polymorphisms in TLR2 and meningococcal infec-
tions has not been studied. TLRs recognise ligands in the
presence of CD14 and MD-2 (TLR4) and activation of the
diverse TLRs results in the activation of different signalling
pathways, leading to NF-B activation. Polymorphisms in
the factors which are involved in these signalling pathways
may also result in different phenotypes.
LBP and BPI
In blood LPS binds to lipopolysaccharide-binding protein
(LBP) to form a complex that binds TLR4. In a recent study
the Cys98Gly and Pro436Leu polymorphisms of LBP
were not correlated with the susceptibility to or severity 
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Figure 1
The three main cascades involved in the pathophysiology of meningococcal infection
The factors depicted in bold are discussed in the text. Adapted from Harcourt Publishers Ltd.
of bacterial sepsis in all patients but a relationship was
found with the outcome of bacterial sepsis in males. It has
been proposed that these polymorphisms may partially
explain the worse outcome of bacterial infections observed
in males. In the same study the clinical effects of poly-
morphisms in bactericidal/permeability-increasing (BPI)
protein were also evaluated. BPI is another protein binding
to LPS which inhibits LPS-induced host cell responses.
Neither the A645G, the G545C silent polymorphism, nor the
PstI in intron 5 were associated with outcome and severity
of bacterial sepsis. However, in this study the limited number
of patients prevented a separate analysis of patients with
Gram-negative versus Gram-positive infections, thus intro-
ducing a bias with respect to LPS-related susceptibility.
This may have limited the sensitivity in detecting an
association.8
C O M P L E M E N T
MBL
Activation of the complement system forms a significant part
of the innate immunity. Besides beneficial, also deleterious
effects are associated with complement activation. The
severity of hypotension is in part regulated by complement
activation. At present, three activation pathways are consider-
ed (figure 2).9 Firstly, the classical pathway which is activated
by antibody-antigen interactions, and secondly, the two path-
ways of the innate immunity, which do not require antibody.
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Table 1
Genetic polymorphisms possibly associated with meningo-
coccal infection (for details see text)
PATHWAY GENE POLYMORPHISM
Innate TLR4 Asp299Gly
immunity LBP Cys98Gly
Pro436Leu
BPI A645G
G545C
PstI in intron 5
MBL Codon 52
Codon 54
Codon 57
Acquired FcRIIa His131Arg
immunity FcRIIIa Val158Phe
FcRIIIb NA1/NA2
Coagulation/ t-PA Alu repeat insertion/deletion
fibrinolysis PAI-1 4G/5G insertion/deletion
Factor V FVL G1691A
Cytokines TNF- G-308A
IL1RN 86 bp repeat in intron 2 
T2018C
IL1B C-511T
IL-6 G-174C
Lectin
pathway
Alternative
pathway
Classical
pathway
Antibody
MBL
C3b
C3
Factor B
Factor D
Factor P
C1q
C1r & C1s C4
C2
C4
C2
MASP 1
MASP 2
Regulators
H & 1
Inflammation
C3a
C3a
Regulators
H & 1
Microbial
surface
Regulators
H & 1
MAC
C5b-C9
Figure 2
The three pathways of complement activation, connecting into a common late pathway generating the membrane attack
complex (MAC) and inflammatory mediators C3a and C5a
Adapted from Hibberd et al.9
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The alternative pathway of innate immunity is activated
through interaction of C3 with factor b, factor d and pro-
perdin to generate C3b. The additional innate activation
pathway is activated through mannose-binding lectin (MBL).
All three pathways converge in a common final pathway.
MBL first forms trimers, which in turn further assemble to
form multimers. The MBL multimers bind to sugars and
LPS on the bacterial surface. This complex then activates the
mannose-associated serine proteases MASP1 and MASP2.
MASPs activate C4 of the classical pathway.
Three allelic variants of MBL have been described in codons
52, 54 and 57 of exon 1. A mutation in codons 54 and 57
causes the disruption of the axial glycine repeats (Gly-Xaa-
Yaa) resulting in aberrant trimers. These trimers cannot
form correct multimers and are unstable. Through an
unknown mechanism, the codon 52 mutation also results
in unstable trimers. Heterozygotes for the variant alleles
show a decrease in MBL serum levels to 10% of normal,
while in people homozygous for any of the three mutations
levels drop to 1% of normal.9,10 In children the variant
alleles were associated with an increased susceptibility to
meningococcal infections. Patients homozygous for the
variant alleles showed a trend towards slightly less severe
disease than heterozygous and wild-type individuals. This
observation, however, did not reach significance.11
LCCD and factor D 
Patients with late complement component deficiency (C5-C9)
(LCCD) are known to suffer from recurrent Gram-negative
bacterial infections. Failure to form a membrane attack
complex (MAC) might underlie this increased susceptibility.
Interestingly, these infections result in milder disease
severity than observed for the total patient population,
suggesting that there are also adverse effects of complement
activation during meningococcal infections. Complement
D deficiency was found in members of a family suffering
from severe N. meningitidis infections. The alternative
pathway for complement activation was impaired. This
pathway, in contrast to the classical pathway, appears to
be prominent in meningococcal infection.12,13
A C Q U I R E D  I M M U N I T Y
Fc receptors
Fc receptors (FcRs) belong to a heterogeneous family of
receptors and are grouped in three classes (FcRI, II and III).
Three subtypes of receptors responsible for IgG-mediated
signalling, FcRIIa, FcRIIIa and FcRIIIb, are thought to
be important in host defence against meningococci. FcRIIa
is located on leucocytes and mononuclear macrophages
and is sensitive to IgG2 and IgG3. Two alleles are known
to differ at amino acid position 131 because of single-nucleo-
tide polymorphism (SNP) in exon 4. The 131Arg allotype
confers lower interaction efficiency on IgG2 and IgG3 than
the 131His haplotype. Two allotypes known for FcRIIIa,
158Phe and 158Val show different binding of IgG1, IgG3
and IgG4, as interaction with FcRIIIa-158Val is stronger.
FcRIIIb is expressed on neutrophils and has the neutrophil
antigen (NA) polymorphism representing four amino acid
substitutions in the membrane-distal loop of the receptor.
FcRIIIb-NA2 binds IgG1 and IgG3 less efficiently than
FcRIIIb-NA.14 One can imagine that differences in effi-
ciency in binding IgGs result in different host response
effectiveness and thereby variable susceptibility to and/or
severity of disease.
A study in survivors of meningococcal disease and first-
degree relatives of survivors and nonsurvivors revealed no
differences in FcR distribution. The FcRIIa-131Arg allele
was more often found in meningitis patients compared
with sepsis patients. The FcRIIIa-158Val allelic frequency
was markedly increased in relatives of meningitis patients
compared with relatives of patients presenting with haemo-
dynamic instability. The Arg/Arg-Phe/Phe-NA2/2 frequency
that represents the least efficient FcR combination, and
is responsible for diminished phagocytosis, was tripled in
first-degree relatives compared with healthy nonrelated
controls. These data suggest an association between FcR
haplotype and susceptibility to and severity of meningo-
coccal disease.14
C O A G U L A T I O N
Activation of coagulation and fibrinolysis is the result of
the acute inflammatory response in patients with invasive
meningococcal disease. The prothrombotic endothelium
surface results from activation by cytokines.
Subsequently, tissue factor production results in activation
of the extrinsic pathway of coagulation and the production
of platelet-activating factors. The fibrinolytic system is
initially activated but is subsequently inhibited. This results
in a marked imbalance in coagulation and fibrinolysis
resulting in a net procoagulant state and ultimately dis-
seminated intravascular coagulation (DIC). This leads to
deposition of fibrin, the formation of microthrombi and
bleeding. Multiorgan failure and death are the most severe
clinical findings regarding this imbalance.
t-PA
Tissue-type plasminogen activator (t-PA) is a serine protease
that converts plasminogen into its active form, plasmin,
which in turn leads to fibrinolysis. Impaired t-PA function
leads to insufficient lysis of thrombi. Differences in t-PA
production or impaired function can therefore affect the
severity of meningococcal disease. An insertion/deletion
polymorphism of an Alu element in t-PA considered to
affect the basal levels of t-PA has been investigated in
relation to meningococcal disease. No association could
be observed between the different alleles and the severity
or outcome of meningococcal disease.15 The authors have
regarded the use of an intensive care unit (ICU) as a criterion
for severe meningococcal disease. In our opinion this only
holds partially true, since not all patients admitted to the
ICU for observation because they are at risk of septic shock
actually develop septic shock. This might have prevented
them from finding significant differences between the study
populations. Further research regarding polymorphisms
in t-PA with respect to meningococcal disease is therefore
indicated.
PAI-1
Plasminogen activator inhibitor type 1 (PAI-1) is responsible
for the inhibition of fibrinolysis both directly and indirectly
through inhibition of t-PA (figure 3). In turn PAI-1 is
inhibited by activated protein C. In septic shock, laboratory
findings show decreased levels of all coagulation factors
including protein C.16 The gene encoding PAI-1 has several
polymorphic loci, including a 3’-HindIII site, a CA(n) repeat
in intron 3 and a 4G/5G insertion/deletion polymorphism
at -675 in the promoter. PAI-1 activity has been shown to be
significantly higher in control subjects homozygous for the
4G allele than in subjects homozygous for the 5G allele.17
The production of PAI-1 mRNA after IL-1 stimulation
appeared to be higher in HepG2 cells bearing the 4G
allele.18 In patients with meningococcal sepsis the levels of
PAI-1 are positively related to severity of disease, outcome,
cytokine levels, acute-phase proteins and coagulation para-
meters.16 In nonsurvivors the PAI-1 levels were shown to
be 1.9 times higher for the same TNF- levels than in
survivors. In children suffering from meningococcal disease
a relationship has been observed between genotype, PAI-1
levels and outcome of disease. The subjects with the 4G
homozygous genotype had higher PAI-1 levels and had an
increased risk of death. No association was observed with
severity of disease.19
A similar study performed by Westendorp et al. showed a
higher incidence of the 5G/5G genotype among relatives
of patients with meningitis. Patients whose relatives were
carriers of the 4G/4G genotype had a sixfold higher risk
of developing septic shock than meningitis.20
FVL
Factor V Leiden (FVL) is associated with thrombotic events,
and is therefore an interesting candidate for involvement
in the development of meningococcal purpura fulminans.
A study comparing children with meningococcal disease,
healthy controls and parents of children with meningococcal
disease did not reveal an association between the FVL
mutation and susceptibility. Patients heterozygous for the
mutation showed increased complications, as assessed by
requirement for skin grafting, referral to plastic surgeon
and/or amputation. A significant effect on mortality was
not observed.21
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Involvement of PAI-1 and t-PA in coagulation and fibrinolysis
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C Y T O K I N E S
TNF-
Tumour necrosis factor  (TNF-) plays a central role in
the activation of the inflammatory response, and serum
levels are raised in all patients with meningococcal disease.
TNF- activates adhesion-promoting receptors and ligands
enabling leucocytes to cross the endothelium and reach
the site of inflammation. Other inflammatory mediators
such as IFN-, IL-6 and IL-8 are activated by TNF-. A
procoagulant state is promoted by the induction of tissue
factor release. TNF- blood levels are positively associated
with disease severity, coagulopathies and outcome.22
Westendorp et al. found a higher TNF- response in ex vivo
blood samples after stimulation with endotoxin in patients
who had experienced a moderately severe disease course
compared with patients with a mild course. The TNF-
response was low again in survivors of fulminant disease.
On admission for meningococcal disease, patients who
did not survive had initial TNF- levels three times higher
than those in survivors with a clinical disease presentation
of similar severity.23,24
The G-308A polymorphism in the TNF- promoter region
has been shown to be associated with outcome of meningo-
coccal disease. The TNF2 allele (-308A) is associated with
an increased risk of death. Controversial opinions exist about
the role of this polymorphism and the severity of disease.
The diverse results of the various studies may reflect the
differences in patient and control populations. Some
researchers study meningococcal sepsis only, while others
look into the relevance of the G-308A polymorphism in
patients suffering from sepsis on an ICU after surgery.25-27
No association has been observed for the G-308A poly-
morphism and susceptibility to meningococcal disease.25,26
It is clear that TNF- production is influenced by genetic
factors in meningococcal sepsis, but the relative importance
of the known polymorphisms is still under discussion.
IL-1 family
The interleukin-1 (IL-1) family consists of both proinflam-
matory and counterinflammatory members. The genes IL1A
and IL1B encode the proinflammatory proteins IL-1 and
IL-1, respectively. The IL-1 receptor antagonist (IL-1RA)
represents the anti-inflammatory component. IL-1RA can
bind the IL-1 receptor without inducing signal transduction.
Several polymorphisms are known in the IL-1 family. Five
alleles of IL1RN, the gene encoding IL-1RA, are known to
differ by a variable number repeat of 86 bp in intron 2.28
This repeat contains transcription factor binding sites.
The IL1RNA2 allele has two repeats and is in linkage dis-
equilibrium with SNP T8006, also known as T2018C.29,30
The A2 allele has been shown to be associated with
susceptibility to severe sepsis in patients in a surgical
intensive care unit.31 Read et al. have investigated whether
variants of the IL-1 and TNF gene families are associated
with severe manifestations of meningococcal infection. All
patients included had microbiologically proven infection
by N. meningitidis. A significant association has been found
between the outcome and the IL1B C-511T polymorphism.
Patients homozygous for either the common or the rare
allele had increased odds ratios for death, compared with
heterozygous individuals. The combination of heterozygosity
of IL1B (-511) together with homozygosity of the common
allele of IL1RN at +2018 was significantly associated with
survival. In this study no association between the TNF -308
genotype and fatal outcome was demonstrated.30 These data
suggest that IL-1 genotype influences the outcome of
meningococcal disease.
IL-6
Interleukin 6 (IL-6) is a major pyrogen and is responsible
for the induction of hepatic acute-phase proteins and anti-
body production by B cells. IL-6 blood levels are increased
in meningococcal infection.32 The G-174C polymorphism
in the promoter region of IL-6 is associated with outcome
in meningococcal infection, since the -174G/G genotype is
associated with an increased mortality risk.33 However, this
polymorphism is part of a complex haplotype associated with
differences in IL-6 production. The -579G, -572G, -373A9/T11,
-174G haplotype shows higher transcription of IL-6 in an
ECV304 cell line after IL-1 induction than the other poly-
morphism combinations. This study clearly shows that
different polymorphisms can have an influence on trans-
cription, but they are not functioning independently.34 When
assessing the contribution of the G-174C polymorphism
in meningococcal disease, the complete haplotype should
be considered.
D I S C U S S I O N
Meningococcal disease comprises a complex pathophysiology
resulting in a spectrum of disease presentation in affected
individuals. Assessing the contribution of host factors in
infection therefore requires a strict definition of the patient
population. Patients suffering from meningococcal
meningitis might have different ‘susceptibility genotypes’
to septic shock patients, as different pathophysiological
pathways are activated. Combining these study populations
is therefore not advisable. The same problems occur when
comparing patients with sepsis of unknown microbiological
origin. Host response to Gram-positive microbes might differ
from the response towards Gram-negative bacteria.4 It must
be noted, however, that in approximately 10% meningo-
coccal infection cannot be proven with microbiological
techniques, while the clinical presentation is typical.
In addition, it might be difficult to obtain patient groups of
sufficient numbers to show an association between disease
susceptibility, severity and outcome when investigating
genotypes with extremely low allele frequencies. Ethnic
differences in the study population might also interfere
with the supposed associations. Studies including relatives
of patients as controls might overcome this problem. These
studies compare the observed and expected inheritance of
the different alleles. One must, however, consider the
possibility that disease is not linked to the studied gene,
but to another gene in linkage with the first. 
Another interesting focus of investigation is the interaction
of the polymorphisms and the cumulative effect on the
course of meningococcal disease. These interactions might
be either synergistic or counteracting. In the IL-1 family such
interactions have been found for IL-1B(-511) and IL1RN
(2018). The development of high-throughput molecular
genetic techniques is of great importance in our efforts to
unravel the immense complexity of genetic interactions.
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Discussion following lecture by P.W.M. Hermans
Netea: I would like to ask you two questions; one is regarding
the tumour necrosis factor (TNF) levels in meningococcal
sepsis. You told us that they are high and that this increases
the severity and the risk of death. Is this really an increased
production capacity leading to death and leading to increased
circulating levels, or is there actually a reduced production
capacity leading to multiplication of bacteria, which leads
to a lot of stimulus, which then leads to high amounts of
cytokines? I am thinking of first-degree relatives of patients
with meningococcal sepsis. If I remember rightly, they
have a reduced production capacity of TNF. My second
question is a more conceptual one, which is more or less
for everybody. As we are now looking at Toll-like receptor
(TLR) polymorphisms in various diseases, what are our
chances of finding something important with a genetic
approach? Because at the moment we find a very significant
polymorphism or a very significant mutated gene, the
host is already dead. So the closer we are to the truth in
looking for a determinant gene, the smaller the chance
we will ever find it. Only less significant polymorphisms
are found which are compatible with survival, whereas
the really significant ones are not detected since the hosts
are already dead. I am thinking of TLRs, because if it is
really a polymorphism which leads to a TLR-2 defect, I do
not think this is compatible with survival. It may be the same
with some important polymorphisms for TNF. For example,
I do not know anyone who is really deficient in TNF.
Hermans: Quite complex comments, but starting with the
last part, I think it is absolutely true that quite a few inter-
esting polymorphisms have been studied now, and as soon
as new polymorphisms pop up, I immediately get the 
feeling, OK, we have to increase the number of patients
again to see any relevance in interaction. You are in fact
driving towards a complete human-specific genetic passport
for that particular human being. If I have got your point
right, I think that these extremely complex and difficult
studies might not give us the appropriate answers we were
hoping for. Coming back to TNF, TNF- expression actually,
for many cytokines, when patients come in, as far as I
understand from the clinicians, the cytokine responses and
the cytokine levels are extremely high. Immediately after
admission they tend to decrease, do you agree, Dr van
Deuren?
Van Deuren: Yes.
Hermans: The turnover is extremely high, which means
that the half-life is quite short. 
Netea: I am just thinking that the circulating levels that you
are measuring are in fact a result of the interaction between
our capacity to make it and how many bugs are multiplying
in our system. It is very difficult to discern and to say, a
sick person has a lot of TNF, so that is a bad thing. It might
very well be possible he was unable to make enough in the
beginning to suppress the multiplication of the bacteria.
Hermans: I agree with that.
Van Deuren: I would like to ask a few questions and make
a few remarks on meningococcal disease. Of course, it is
a blood-borne infection with an impressive clinical picture
and blood is the most easily obtained tissue. So a lot of
measurements have been done in blood. But it is really
the question whether that is the most important site of the
body to look at. The gate for the meningococcal bacterium
is the oronasal mucosa. At that site there are several inter-
actions between the bacterium and our immune system:
the meningococcal pylus is attached to CD46 for instance,
the meningococcal pore A outer membrane protein is
attached to the carcinoembryogenic antigen CEA, CD66a,
b and c. And there are a lot of polymorphisms in these
types of receptors or ligands too, for instance relating to
the intramucosal survival of the meningococcus, because
it is able to survive passing through the cells. There are
some studies showing that they are influencing bactericidal
proteins, enabling them to survive and to pass through
the bloodstream. Are you aware of any studies looking at
the polymorphisms in this site of the body? Because that
will really determine our susceptibility, because all the rest
in the blood really is a matter of severity.
Hermans: As far as I know, such studies have not been
undertaken, but the initial point you made that has not been
studied either, in detail at least, is the genetic differences
among these bugs, and it is definitely not only man C
versus man B, but there are many more molecules showing
a huge variety within this particular species.
Van Deuren: That is the second important property of the
bug, of course, its switching off and switching on molecules
so rapidly enabling it to enter the bloodstream. A second
remark about the levels of TNF: the higher the concentration
of endotoxin in your blood, the more TNF you produce.
And really the best predictor of mortality is not the TNF
level but the endotoxin level, as already mentioned by
Brandtzaeg in his series of 150 patients. There is a good
correlation between the level of TNF and endotoxin. So for
me it is not the genetic trait or the capacity of the person
to produce TNF, but it is the amount of endotoxin that he
tolerates, and that will determine the amount of TNF
produced and, thus, the amount of procoagulant and
anticoagulant activities.
Appelmelk: You showed that you get an impressive increase
in relative risk when you add the various polymorphisms.
Where will this end? From a scientific point of view you can
go on, but do we need to know all this? Which knowledge
regarding polymorphisms will lead to clinical actions?
You read in the papers about DNA passports and you see
companies eager for dollars, but how important is it for
the actual patient management?
Hermans: Your question actually was the main reason for
me to show this study on tissue-type plasminogen activator
(t-PA) therapy, which is in part guided by the existing
polymorphisms and genetic variability. Indeed, when you
have these details, there is a possibility of performing
patient-specific therapy in the long run. At the moment
that is not feasible. But I think such data are of definite
value for the patient. It is not so that you are just born
with a ‘genetic passport’ and that nobody can change
anything about that. I think when you have these data in
advance and you know where to interact, you can intervene
in these processes.
Appelmelk: Do you think that it is realistic when we have a
patient and are at the bedside to take his blood, for us to
put it on a chip and then decide what to do? 
Hermans: By that time it is too late!
Kusters: Can I give one brief comment or ask a question?
You are now looking at only one type of disease and one
type of bug trying to find the ideal ‘genetic passport’, but
obviously evolution has gone a long way and the so-called
wrong passport may in fact be an ideal passport for survival.
Maybe an increased risk of a certain type of disease is the
flip side of a better survival of other types of disease.
Hermans: When a patient comes in with a meningococcal
sepsis, having an excellent overall survival passport, still
at that time his survival clock has started ticking towards
zero. When you know the disadvantages of that particular
passport, if you can alter it, that would be a major advantage.
Of course, such an intervention might be disadvantageous
with another infection.
Kuijpers: Whether lipopolysaccharide (LPS) and the levels
of TNF strictly correlate, depends on which test system
you use, which ELISA, or especially which firm you
have addressed to purchase this ELISA system from. Just
comparing TNF ELISA test systems as such would already
give you two or three papers probably. It is very difficult.
With genes you cannot lie – that is an advantage, but on
the other hand it is of course a disadvantage that if you
then start to shift from genes to concepts, as for instance
TNF-induced responses, and one observes the staggering
lack of effect of blocking TNF for instance in meningococcal
disease or sepsis, I very much doubt whether this approach
will have any impact in the short run on how to treat patients.
Kimman: It is nice to comment on this issue of course,
whether we should do this work in order to improve the
treatment of individual patients. I do not see a future in
which patients will be treated only after their genotype has
been assessed, but on the other hand, you nicely showed
that this kind of work can lead the way to pathways which
can be influenced whatever the genotype of the patient is.
For instance, you identify a PAI/t-PA pathway and then
you have a lead for treatment irrespective of the genotype
of the patient. Unfortunately it did not work, but you
identified something which you can tackle.
De Groot: I would like to support Dr Hermans in relation
to the question from Dr Appelmelk and the point that is
raised here. I will give you a practical example why I think
this genetic approach will have additional value and how
it could already have in the current situation. Let’s consider
a polytrauma patient and suppose you knew the genetic
profile in advance when he came in, thus being able to
predict whether he was in a high-risk group or in a low-risk
one. That would be helpful in the choice of therapy. Now
Dr Hermans mentioned one therapy, t-PA, but another one
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is known to all clinicians from a publication in the New
England Journal of Medicine last year, namely activated
protein C.1 Both therapies have serious potential side
effects in terms of cerebral haemorrhage. The selection 
of patients who would benefit from these very invasive
therapies would therefore be balanced depending on their
risk. So this is the way of thinking I believe we should
pursue as clinicians in terms of making a choice actually
for these drugs where we know that in these desperately
ill patients there certainly will be a very narrow kind of
safety margin.
Van Deuren: Just to address a limitation of this approach. In
meningococcal disease I have looked at the moment – I call
it the kinetics of dying – the patient dies from that disease.
From literature and from my own experience I have collected
approximately 300 deaths, not cases, but deaths, and from
that it can be seen that one-third of the patients who will
die have already died within six hours of admission, half
have died within 12 hours, 66% within 24 hours and 80%
within 48 hours. So already one-third of your patients
have been lost within six hours. I do not know how long
it takes to run a chip array.
Verbrugh: It is quite interesting that we are here discussing
the value of our core business as a science, the creation of
new knowledge. We would rather like to pose the question
beforehand or we would like to know which knowledge
we can use and what knowledge we cannot. This is a poor
question to ask. Sometimes we do have to ask, because
there are financial constraints, but primarily the business
is to get new insights and new knowledge. 
R E F E R E N C E
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O U T L I N E
Protective immunity to intracellular pathogens such as
mycobacteria and salmonellae depends on effective cell-
mediated immunity (CMI) in which T-cell-macrophage
interactions play a crucial role.2 A major effector mechanism
of CMI is the activation of infected macrophages by type-1
cytokines, particularly interferon-gamma (IFN-).2 IFN-
is produced by antigen-specific T-helper 1 (Th1) cells and
natural killer (NK) cells, and binds to IFN-R1/R2 receptor
complexes at the cell surface of macrophages. 
The production of IFN- by T cells and NK cells itself is
tightly regulated by another cytokine, interleukin-12 (IL-12).
IL-12 is a heterodimer, composed of a p40 and a p35 sub-
unit, and is produced by antigen-presenting cells such as
macrophages, monocytes and dendritic cells2 following
the activation of Toll-like receptors by bacterial ligands.3
Thus, IL-12 plays a major role in promoting and linking
both innate and adaptive immunity. IL-12 binds to IL-12
receptor 1/2 complexes at the surface of Th1 and NK cells.
Whereas IL-12p40 predominantly interacts with the IL-12R1
chain, IL-12p35 primarily binds to IL-12R2. Two additional
cytokines with IL-12-like activities have recently been iden-
tified, namely IL-18 and IL-23, both of which are produced
by antigen-presenting cells. IL-18 acts mainly in synergy
with IL-12 and plays an accessory role in promoting optimal
IFN- production.4 Interestingly, IL-23 shares one subunit
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A B S T R A C T
Human genetic factors play an important role in determining the outcome of infections caused by intracellular pathogens,
including mycobacteria and salmonellae.1 The genetic elements involved and the mechanisms by which these control disease
susceptibility vs resistance, however, remain incompletely characterised. Recent studies on patients with idiopathic severe
infections due to otherwise poorly pathogenic mycobacteria (nontuberculous mycobacteria or Mycobacterium bovis BCG)
or Salmonella species have revealed that many of these patients are unable to produce or respond to IFN-. This inability
results from causative, deleterious genetic mutations in any one of five different genes in the type-1 cytokine cascade,
encoding IL-12p40, IL-12R1, IFN-R1, IFN-R2 or STAT1. The mutational events can lead to complete or partial deficiency,
and are mostly autosomal recessive but can be dominant negative as well. The immunological, clinical and histopathological
phenotypes resulting from the 11 groups of genetic type-1 cytokine (receptor) deficiencies that have been identified thus
far differ significantly. These findings are summarised, discussed and placed in a broader context in relation to genetic
disease predisposition and molecular and cellular mechanisms of protective immunity to these intracellular pathogens. 
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with IL-12, notably p40, which is coupled to a unique second
chain, p19.5 Similarly, the receptor for IL-23 consists of an
IL-12R1 subunit which is complexed to an as yet uniden-
tified p19R chain. As expected, IL-12 and IL-23 display
similar functions, including the stimulation of IFN-
production, although their functional profiles are not
completely identical.5 Other cytokines can act as additional
factors in promoting Th1 development and IFN- production,
such as the recently identified TCCR ligand,6 interferon-
and chemokines.7
IFN-, in synergy with TNF-, is able to activate microbicidal
mechanisms with antimycobacterial activity in murine
macrophages.8 Although IFN- is clearly able to affect the
growth of M. bovis BCG also in human macrophages,
reports on a similar role for IFN- in M. tuberculosis-infected
human macrophages have been conflicting.8 Recent evi-
dence now suggests that IFN- may require the presence
of other factors, such as 1,25-dihydroxy-vitamin D3 and
TNF-, or human lymphocytes, in order to exhibit anti-
M. tuberculosis activity in human macrophages, but this
issue clearly needs further study.9 Furthermore, IFN- is
well known to enhance MHC class I and II expression and
to modulate the expression of other molecules involved in
antigen presentation, such as proteasomes and transporters-
associated-with-antigen-processing (TAP), thus promoting
optimal CD4 and CD8 T-cell activation.10 An additional
component of CMI is the activation of cytolytic effector T cells
that are able to kill infected macrophages, thereby inhibiting
bacterial proliferation through a variety of mechanisms.11
Effective CMI typically leads to the local containment of
the pathogen inside well-organised granulomatous lesions,
with epitheloid and giant cell formation and relatively few
detectable micro-organisms.
Recently, several patients have been reported with unusually
severe and sometimes fatal infections due to usually poorly
pathogenic mycobacteria, in the absence of any recognised
primary or secondary immunodeficiencies. These patients
mostly suffered from infections due to M. avium, other
nontuberculous mycobacterial species or M. bovis BCG,
but also other pathogens have been reported including
salmonellae and M. tuberculosis. The patients described
thus far often fail to form well-organised granulomata at the
sites of their lesions. A common feature of these individuals
was their inability to produce or respond to IFN- in vitro.
This appeared to be due to deleterious mutations in any
one of five different genes in the type-1 cytokine cascade,
notably IL12B (encoding IL-12 p40), IL12RB1 (encoding
IL-12R1), IFNGR1, IFNGR2 (encoding IFN-R1 and
IFN-R2 chains, respectively) or STAT1 (encoding IFN-R-
associated STAT1). The mutational events resulted in either (i)
recessive, nonfunctional null alleles, (ii) recessive, partially
functional alleles, or (iii) dominant-negative alleles, causing
partial functionality. Upon further analysis, these deleterious
mutations appear to comprise a spectrum of genetically
controlled deficiencies in which the extent of the defect
correlates with the severity of the clinical, immunological,
and histopathological phenotypes observed. 
Recent developments and findings regarding defects in the
IL-12/IL-12R and IFN-/IFN-R/STAT1 systems respectively
will be discussed.12,13 These novel defects reveal essential
molecular and cellular mechanisms of protective cell-
mediated immunity against intracellular pathogens. The
intriguing observation that these patients appear to be
selectively susceptible to otherwise poorly pathogenic myco-
bacteria and Salmonella species will be discussed as well.
Finally, comparison of the different clinical, immunological
and cellular phenotypes in the various types of genetic
defects reveals a spectrum of genetic disorders, which
establishes genotype-phenotype relationships but also
elucidates additional host- or environment-dependent
variability in disease manifestations.
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Van der Meer: Regarding the interaction between the T
lymphocyte and the macrophage, you did not point to defects
of IL-18. The question is, of course, is IL-18 an irrelevant
molecule, didn’t we look carefully enough, or could it be
that the IL-23/IL-12 combination takes out enough of the
redundancy to cause trouble. 
Ottenhoff: We have not been able to find any defects in IL-18
production and IL-18 receptor expression in those patients
we have analysed. Other laboratories did not find any
mutations or defects in that system either. In my view IL-18
is mainly an amplifier of IL-12 and perhaps also IL-23. Maybe
IL-18 deficiency is not sufficient to cause a dramatically
enhanced disease susceptibility to mycobacteria. 
Netea: You have also investigated the patients with receptor
defects for IL-12 and interferon- and found no difference
in IL-18 receptor expression? 
Ottenhoff: Correct.
Netea: One of the mechanisms for the synergism between
IL-12 and IL-18 could be that IL-12 actually induces expres-
sion of IL-18, and IL-18 would do a lot of the work.
Ottenhoff: If you activate the cells with phytohaemagglutinin
(PHA), you see normal expression of the IL-18 receptor 
component. So that certainly is not IL-12-dependent in
that system, or at least not IL-12-receptor-1-dependent.
Netea: But I don’t know whether PHA is a relevant stimulus.
Could it be going to the T cell directly without the need of
a macrophage?
Ottenhoff: PHA is a good system to screen for major defects,
but physiologically IL-18 actually could contribute.
Netea: Have you looked at the IL-18 receptor in these patients
with IL-12 receptor defects? 
Ottenhoff: Yes, we looked at it, but in these patients there
is no defect in IL-18 receptor  expression.
Netea: That would imply that those who are saying that
IL-12 is working through induction of IL-18 receptor are
probably wrong?
Ottenhoff: That is true. We have published this.1 If you
activate T cells in patients with IL12R-1 defects, there is
a small residual IL-12 response. This is of course 1
STAT4-independent, and most likely works through MAP
kinase. Perhaps that pathway would be sufficient to induce
IL-18 receptor expression in these patients. 
Van Furth: Do you have an explanation for the occurrence
of tuberculosis, which only arose in three patients, and the
other mycobacterial infections, while activation of macro-
phages is only mildly affected? In contrast, AIDS patients
develop tuberculosis early on, and when the CD4 count is
really low infections with other mycobacteria develop. 
Ottenhoff: One explanation for this paradox is that there is
no exposure of these patients, who are mainly from Western
countries, to M. tuberculosis. Another explanation is that in
endemic areas these patients die prematurely and a genetic
diagnosis is never made. A third option is that once a
patient presents with TB, a genetic defect is not considered.
In the three TB cases that have been reported so far this
was more or less discovered by coincidence. These defects
may be more common in tuberculosis. A fourth, less likely
and more academic option is that M. tuberculosis inhibits,
at least in part, signalling through the interferon- receptor
STAT1 pathway in macrophages. Because M. tuberculosis
does this, the macrophage may be less sensitive to inter-
feron-, and therefore in TB such defects would have less
impact than for instance in BCG or M. avium.
De Jongh: Sarcoidosis has many similarities with tuber-
culosis. Are there defects in patients with sarcoidosis?
Ottenhoff: We have tested about ten sarcoidosis patients,
but it is too early to say.
Kuijpers: Interferon- receptor-deficient patients may have
an increased susceptibility to viral diseases.2 It is a very
weak association, but isn’t it the biggest surprise that it is
so monogenic?
Ottenhoff: I agree. That is why I concluded that quantitative
ligation of the interferon- receptor is important. It indicates
how important full-blown activation through the inter-
feron- receptor pathway is for protection. I think in the
case of viral infections or toxoplasmosis, there may be
sufficient backup pathways to compensate for these defects,
but in the case of mycobacterial and salmonella infection
these are not sufficient.
McAdam: What about the ages of the patients with the
defects? You suggested the poor life expectancy in the tropics.
Certainly we have screened for type-1 pathway defects in
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our adult TB patients and have not found any, but that
probably means that the others died of viral infections or
something else much younger. 
Ottenhoff: Patients with complete interferon- receptor 1
and 2 defects usually present during early life and quite
often die before the age of ten. So that is really a severe,
often fatal syndrome. IL-12 receptor deficiencies are a little
less severe. Those patients can present at an early age but
even at 30 years and older. They often survive quite long.
De Groot: Do you have data on the genetics of parents, grand-
parents and other family members, and have you gone back
some generations to see if there were comparable diseases?
Ottenhoff: Yes, all the families we have analysed from Turkey
are consanguineous. They can be traced back to one prece-
dent generation. The parents are always heterozygous for
the mutations. We performed extensive family analyses
and showed that these really segregated recessive traits,
as you would expect. At the moment we are investigating
whether there are founder effects in Turkey, if certain alleles
are more common in the population than other alleles,
and if these alleles are maintained in the population and
sometimes cause major disease in these families.
De Groot: How would this fit in with the theories on HLA
and genetic susceptibility at population level? By changing
the HLA make-up over generations apparently disease
becomes modified? How does this relate to these cellular
defects?
Ottenhoff: That is a difficult question. The defects I described
work at the level of innate immunity as well as of the
adaptive immunity: first there will be a major deficiency
in innate immunity, and this will later on also lead to a
major defect in acquired immunity. At that stage there is
interaction with HLA leading to enhancement or a decreased
susceptibility. These genes I have discussed have a major
impact, especially on the early, innate phase, at that stage
of course apart from HLA. 
De Vries: Also, such a rare mutant, which results in a rather
severe phenotype, works out in a recessive way. The genetic
situation is completely different when you are talking
about HLA alleles which are polymorphic at relatively
high frequencies, and which are working in a dominant
or co-dominant way. This situation is open to selection. 
Netea: Regarding IL-12 p40, could it be, for example, that
there are TB patients who produce too much p40 and in that
way would be blocking the normal p40/p35 heterodimer
action?
Ottenhoff: There is great variation in p40 production between
different individuals, that I know, but I am not aware that
this is related to tuberculosis.
Appelmelk: I am curious, how are you planning to go on? 
Ottenhoff: It is difficult to decide. Should we opt for a candi-
date gene approach? That is something we are doing. One
of these is the interleukin-10 gene. If you want a totally
unbiased approach you should go for a genome scan and
do linkage analysis and then try to positionally clone the
genes involved. That is not easy. It would be a good idea to
start using micro-arrays and compare genetic expression
profiles of tuberculosis patients with exposed but protected
individuals, and try to find which pathways light up in
susceptible vs protected individuals and to define the
different cascades.
Van Agtmael: Has this pathway been evaluated in the
patients with Legionella, for instance during the recent
outbreak in Bovenkarspel in the Netherlands?
Speelman: I can answer that: with Professor van Dissel we
are investigating this. So far the results have not been very
exciting.
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I N T R O D U C T I O N
Susceptibility to infectious diseases is under polygenic
control, as exemplified by genetic susceptibility to malaria.
Severe Plasmodium falciparum malaria exerts enormous
selective pressure on populations living in malaria-endemic
areas. In the era before the advent of antimalarial medicines,
those who could not survive malaria and develop effective
immunity were wiped out at a young age and only those
who survived were able to pass on their genes to the next
generation. The sickle-cell haemoglobin mutation (S)
confers protection against malaria in its single-dose hetero-
zygote form (AS) and provides a selective advantage, despite
the disadvantage conferred by the two-dose (SS) form in
homozygotes.1 Many genes have now been described as
providing resistance against malaria, including various
haemoglobin variant genes giving rise to thalassaemia2
and glucose-6-dehydrogenase deficiency, as well as class I
and II HLA molecules. HLA B53 is found in 30% of the
Gambian population whereas it is uncommon in Europe.
The nine-amino-acid peptide that fits best in the groove of
HLA-B*53 codes for a portion of the malarial liver-specific
antigen LSA-1, presumably demonstrating that the selective
advantage of B*53 identifies a vulnerable target in the para-
site life cycle. Following on from this work in The Gambia,
new malaria vaccine constructs have been designed to
include this and other liver-stage antigens not previously
considered as vaccine candidates. The promise that iden-
tification of susceptibility/resistance alleles can lead to the
development of new approaches to vaccines or therapeutic
agents has encouraged us in The Gambia to pursue studies
of the genetics of disease susceptibility. We have focused on
important endemic infectious diseases in Africa including
malaria, tuberculosis, hepatitis B, chlamydia and HIV. This
paper briefly summarises our efforts on two candidate genes,
NRAMP 1 and vitamin D receptor, to define susceptibility
to tuberculosis.
G E N E T I C  S U S C E P T I B I L I T Y  T O
T U B E R C U L O S I S
Heritability of tuberculosis has been suggested by various
studies in twins,3 by racial differences in resistance to TB4,5
and by animal studies in rabbits and inbred strains of mice.6,7
Families expressing a high rate of mycobacterial disease
have been important in defining various Mendelian suscep-
tibilities in the interferon- and IL-12 pathways.8-11
Most people who breathe in aerosol droplets containing
M. tuberculosis become infected. However, only 5 to 10%
of close contacts of a case of open pulmonary TB go on to
develop tuberculosis, and it has been assumed that this
susceptibility is related to the effectiveness of the immune
system. Many factors including genetic background influence
the innate and acquired arms of the immune response.
Poor nutrition, alcoholism and immunosuppression due
to drugs or other infections, including HIV and measles,
have been implicated in an increased susceptibility to
TB.
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Resistance to infectious diseases is complex, being regulated by multiple genes, and so far no one locus has been shown
to dominate the susceptibility in outbred human populations. Multi-case families have contributed greatly to defining
important host immune response pathways using a candidate gene approach. It is likely that genome scans will identify
novel genes for resistance to disease that could help define new approaches to drug and vaccine development. 
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An increasing number of genes have been implicated in
susceptibility to tuberculosis. HLA is perhaps the best
documented, with conflicting positive and negative associ-
ations reported. An increased frequency of HLA-DR2 is the
most consistent association but has not been found in all
populations examined, nor was there clear linkage to the
MHC in a genome-wide screen carried out on patients from
The Gambia and South Africa.12
When the Scottish missionary Dr David Livingstone travelled
through Central Africa in the mid 19th century he did not
see a lot of TB, though he would have observed plenty in
Britain. Senegalese troops who fought in the 1914-18 war
contracted TB at a higher rate than European soldiers,
suggesting that they were nonimmune and had not been
exposed to M. tuberculosis previously, or perhaps were more
susceptible genetically. Stead reported that black Americans
in Arkansas nursing homes had twice the risk of acquiring
M. tuberculosis infection compared with white subjects.4
Crowle confirmed a similar trend in vitro, showing that
macrophages from blacks were more easily infected and
less activated by vitamin D.5
V I T A M I N  D  R E C E P T O R  A N D  
T U B E R C U L O S I S
Historically, there has been circumstantial evidence for an
association between vitamin D and tuberculosis. Prior to
effective chemotherapy, patients were sent off to sanatoria
where they were exposed to fresh air and sunlight, which
was thought to provide the best environment for recovery.
Patients with skin TB or lupus vulgaris responded well to
vitamin D therapy but some patients with pulmonary
tuberculosis fared badly. Rook showed that macrophages
stimulated with vitamin D were activated, providing a
rationale for these anecdotal clinical observations.13 The
active form of vitamin D, 1,25 dihydrocholecalciferol (1,25D3),
binds the vitamin D receptor (VDR) in the cytoplasm of
macrophages and activated lymphocytes. VDR is a zinc-finger
DNA-binding transcription factor which migrates to the
nucleus, resulting in the expression of a number of
hormone-sensitive genes.
VDR maps to chromosome 12q13-14, and belongs to the
steroid/thyroid hormone receptor family with 11 exons.
Polymorphisms within the VDR gene include a Taq I site
at codon 352, an Apa I site and a Bsm I site in intron 8
and a Fok I site in exon 2 which leads to an alternative
transcription site. Although the association between VDR
polymorphisms and bone mineral density has been hotly
debated,14 the homozygous Taq I genotype ‘tt’ has been
associated with decreased bone mineral density (osteo-
porosis). Bellamy et al. found this genotype less commonly
in 400 TB cases in The Gambia than in the 400 ethnically
matched controls (odds ratio 0.53, 95% confidence limits
0.31-0.88, p=0.01).15 Wilkinson et al. undertook a case-control
study of Gujarati Indians in West London, demonstrating
an association between TB and a combination of VDR
genotype and serum 1,25D3 concentration.16 Another study
in India did not confirm an association with VDR, though
the TT genotype was overrepresented in female cases
compared with controls.17 Vitamin D receptor polymorphism
has been shown to be relevant to susceptibility to leprosy
in Calcutta, where ‘tt’ was overrepresented in tuberculoid
cases and ‘TT’ was associated with lepromatous disease.18
Interestingly, ‘tt’ has also been associated with enhanced
clearance of Hepatitis B virus, suggesting that 1,25D3 and
VDR may play a more central role in regulating immune
responses against infections.15
N A T U R A L  R E S I S T A N C E  A S S O C I A T E D
M A C R O P H A G E  P R O T E I N  1
Natural resistance associated macrophage protein 1
(NRAMP1) has recently been renamed SLC11A1 (Solute
Carrier family11 member1). Originally described in inbred
mouse strains, this locus was confirmed to be a single gene
on chromosome 1 when a knockout mouse proved NRAMP1
was responsible for resistance to several intracellular
infections.19 A single amino acid change on the 4th trans-
membrane domain of the protein resulted in an absence
of the protein in susceptible mice.7,20 This naturally occur-
ring mutation led to a Gly-Asp substitution at amino acid
169, which enhanced susceptibility in mice to intracellular
infections with leishmania, salmonella, toxoplasma, candida
and mycobacteria.19
In humans the NRAMP1 gene is located on chromosome
2q 3521 and has been associated/linked to various infectious
diseases (tuberculosis, leprosy, [?meningococcal meningitis],
leishmaniasis and HIV) and autoimmune diseases (rheuma-
toid arthritis, diabetes, sarcoidosis, and Crohn’s disease).22-26
In 400 cases and controls in The Gambia, Bellamy and
colleagues have shown that four variants of the NRAMP1
gene are significantly associated with an increased risk of
developing cavitary pulmonary tuberculosis.23 In the patient
group there was an increased risk (odds ratio 4.08, 95%
confidence interval 1.86-9.12, p<0.001) of TB in individuals
heterozygous for both a single nucleotide polymorphism
(SNP) in intron 4 and a ‘TGTG’ deletion in the 3’untranslated
region (3’UTR).23 A family-based study from Guinea-Conakry
confirmed the association with the intron 4 polymorphism27
and a case-control study has confirmed the association with
the 3’UTR deletion in Koreans.28 Gao et al. have found
associations with a 5’ promoter region polymorphism in
Japanese patients.29 Linkage to a chromosome 2 region,
which includes the NRAMP1 gene, has been documented
in a Canadian aboriginal family.30 However, the results
from a linkage study in a Brazilian population showed no
evidence of NRAMP1 involvement in susceptibility to TB.22
Moreover, a genome-wide screen demonstrates that
NRAMP1 is not a major susceptibility gene in Gambians,
in whom only a weakly positive linkage was shown to 2q 35.12
Slc11a1 is found in late endosomes and lysosomes but not
in early endosomal membranes. It is unclear how Slc11a1
functions in the maturation of the phagolysome nor in the
reduced acidification found in mycobacterium-containing
lysosomes. Slc11a1 is a proton/divalent cation transporter
(Fe, Zn, Mn) which can move divalent cations in either
direction against a proton gradient. Thus cations can be
delivered from the cytosol to the acidic compartment of late
endosomes/lysosomes, where they catalyse the production
of reactive oxygen intermediates (ROI) including hydroxyl
radicals. Killing of mycobacteria probably involves both ROIs
as well as reactive nitrogen intermediates (RNI) generated
by nitric oxide synthetase NOS2, and by apoptosis of macro-
phages induced by ATP through the P2X7 receptor.31
Blackwell has defined four alleles containing different
numbers of DNA repeats at positions (i)203, (ii)201, (iii)199
and (iv)189, with allele frequencies of (ii) and (iii) being
0.25 and 0.75 respectively.26 Using a reporter gene system,
LPS drives five to eightfold higher gene expression by
allele (iii) and significant reduction in expression by allele
(ii). They proposed that the higher expressing allele (iii)
with (GT)n polymorphism would be associated with
autoimmune disease and the low-expressing allele (ii) with
infection. Allele frequencies for SLC11A1 allele(ii) are in the
range 0.14 to 0.20 in West and Southern Africa, compared
with 0.25 to 0.29 in Northern Europe and 0.36 in Brazil.
Individuals homozygous for iii/iii produced higher con-
centrations of TNF and were at significantly higher risk
of severe clinical meningococcal disease (Hibbard, Levin
& Blackwell). 
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Discussion following lecture by K.P.W.J. McAdam
Fenton: Are there any data suggesting that similar suscepti-
bility loci are involved in other populations and racial groups?
McAdam: Quite a large number of different places have
been looked at, for instance for HLA. The NRAMP work has
been done in South America, the USA and in Canadian
aboriginals. 
De Vries: For the known four associations – HLA, the vitamin
D receptor, the NRAMP1 and interleukin-1 – there are
several ways to get an idea to what extent they explain the
genetic variability. Has that been studied?
McAdam: My understanding is that the heritability has been
derived from the twin studies. In terms of the individual
genes, not one of those comes up on the whole genome
scan as a susceptibility area for linkage. So I suspect the
contribution is quite small.
Ottenhoff: There was a recent paper by Adrian Hill’s group
showing that there is a major locus at chromosome 10
estimated to contribute up to about 40% of the total genetic
component in leprosy.1 So that is actually quite a large
contribution for a single locus.
De Groot: The paper by Wilkinson et al. on West Gujarati
Indians clearly showed the gene-environment interaction
in an infectious disease.2 Do you know what happened in
the follow-up of this population? Are they prescribing
vitamin D for these people, and does it have an effect on
the susceptibility to tuberculosis?
McAdam: I am told that the authors are not using vitamin D
therapy or suggesting any intervention. I would actually
like to know whether anyone else is considering vitamin
D therapy and how this would be tested. Vitamin D has
been used historically and in the book by Dubos & Dubos it
is recorded that quite a lot of people did worse with vitamin
D therapy.3 They seemed to lyse their lungs. So I’m not
sure about this intervention, except for skin tuberculosis
– there vitamin D is very effective.
Van der Meer: We would rather use vitamin A and zinc
supplementation in view of a placebo-controlled study in
Indonesia in which we were involved.4 After two months
the supplement had a distinct effect on both wellbeing
and the X-ray signs of the tuberculosis. This effect was lost
after six months, probably because there was no resistant
tuberculosis among the patients, and all of them responded
well to the antituberculous drugs which were given con-
comitantly.
McAdam: And the people on isoniazide, did they do as well
as the people on isoniazide plus zinc and vitamin A?
Van der Meer: The latter group did better. All this has still
to be confirmed in a larger independent study.
McAdam: How are we, as a clinical investigating community,
going to respond to genes that are going to be accumulative
in terms of their effect? If you select patients with a par-
ticular vitamin D receptor genotype, you do not actually
know – unless you type their genes – what other suscepti-
bility loci they have. Ottenhoff’s suggestion of using the
array technology to develop a haplotype might have to be
followed before one can actually look at functional genomics.
El-Omar: Quite a number of populations that are predisposed
to tuberculosis also have a high incidence of starvation,
malnutrition, malabsorption enteropathies and so forth.
To what extent do you think these environmental factors are
modifying the genetic constitution in terms of expression
of the disease, either towards susceptibility or towards
responding to the infectious agent?
McAdam: That is a very pertinent question, to which I do
not know the answer. Common sense says it must make
a huge difference, and if you look at animal studies, it does
make a dramatic difference. When you look at guinea pigs
that are fed a protein-deficient diet and then are challenged
with aerosol tuberculosis they die very rapidly, whereas
protein-sufficient animals do not. Of course, many of these
patients, by the time you see them, have a nutritional pro-
blem. With tuberculosis they have lost weight, they have
had fever, they have got lots of inflammatory cytokines on
board. We are doing a prospective case-contact study at
the moment trying to analyse that, but it is not easy to
investigate.
Appelmelk: I am confused about how vitamin D works, if it
works. You stated that it causes macrophage activation and
then bacteria are killed, but at the same time, as you said,
it causes a shift from Th1 to Th2, meaning the opposite.
McAdam: It originates from studies done by Graham Rook
and the supposition is that vitamin D modulates the cytokine
profile, leading to proinflammatory cytokine production.5
Netea: I wonder whether we are on the right track if we are
not taking into account that susceptibility to mycobacteria
may vary depending on the strain. This would hold for
M. tuberculosis versus atypical mycobacteria but perhaps also
within M. tuberculosis isolates. I am thinking for instance
of the Beijing strains.
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I N T R O D U C T I O N
It has long been established that human susceptibility to
infectious agents is at least partly under genetic control.
Several observations from twin, adoptee, pedigree, and
candidate gene studies point to host genetic factors as key
determinants of this susceptibility.1,2 The recent explosion
in genetic knowledge, accelerated by the human genome
project, is helping to unravel the molecular pathways that
mediate genetic susceptibility to human diseases, including
infections and cancer.3-5 While genetic susceptibility may
apply to the risk of acquisition of an infectious agent, it is
becoming increasingly recognised that host genes also
influence the pathophysiological response to infections,
which ultimately determines the clinical outcome.
The role of infectious agents in carcinogenesis has com-
manded significant scientific interest culminating in five
Nobel prizes in the 20th century.6,7 Infections can cause
cancer by a variety of mechanisms including direct trans-
formation of cells, induction of immunosuppression with
consequent reduced cancer immunosurveillance, or by
causing chronic inflammation. The last-mentioned is
becoming increasingly recognised as an essential component
of many epithelial cancers by virtue of its combined effects
of generating genotoxic by-products and increased cellular
proliferation, thus maximising the potential for DNA damage. 
In this article, I hope to demonstrate how interactions
between an infectious agent, host genetic makeup, and
environmental factors could influence the pathogenesis of
a cancer. The infectious agent in question is Helicobacter
pylori, the world’s commonest chronic bacterial infection,
and the malignancy is gastric cancer, second only to lung
cancer in its global incidence and impact. We demonstrate
how this gastric infection could be utilised as a paradigm
for gene-environment interactions in human disease, one
that could help unravel a multitude of other microbially
induced malignancies.
H E L I C O B A C T E R  P Y L O R I I N F E C T I O N
The Helicobacter genus consists of at least 24 species found
in the GI tracts of animals and humans.8 One of these
species is Helicobacter pylori (H. pylori), a Gram-negative,
spiral-shaped, micro-aerophilic, urease-positive bacillus,
which is known to chronically infect the stomachs of over
half the world’s population. The infection is acquired during
childhood, most probably via the faecal/oral or gastric/oral
routes, and if not treated with antibiotics, will persist
throughout life.9 The organism is 2.5 to 5 micrometers long
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Helicobacter pylori infects half the world’s population and is associated with serious human diseases including peptic ulcer
disease and gastric neoplasia. The clinical outcome is largely dependent on the severity and distribution of the H. pylori-induced
gastritis. The reasons for such variable clinical outcomes remain poorly understood. Bacterial virulence factors contribute
to the pathogenicity but do not explain the divergent outcomes. There is emerging evidence that host genetic factors play
a key role in determining the clinical outcome to H. pylori infection. In particular, proinflammatory genotypes of the
interleukin-1 beta (IL-1) gene are associated with increased risk of gastric cancer and its precursors. The effects are most likely
mediated through induction of hypochlorhydria and severe corpus gastritis with subsequent development of gastric atrophy.
In this article we discuss the role of IL-1 and other host genetic factors in the pathogenesis of H. pylori-related disease.
with four to six unipolar flagellae. These flagellae are
thought to allow it to move through the mucus layer within
the stomach and come to reside between this layer and the
gastric epithelium. Eighty percent of the bacilli are free;
however the remainder are attached to epithelial cells. Once
attached, the organism induces ultra-structural changes in
the gastric epithelial cells. Although the bacteria mainly
reside on the surface mucus gel layer with little invasion
of the gastric glands, the host responds with an impressive
humoral and cell-mediated immune response. This immune
response is largely ineffective, however, as most infections
become chronically established with little evidence that
spontaneous clearance occurs.
H. pylori can only proliferate on gastric epithelial cell sur-
faces and in the overlying mucus layer. Thus H. pylori has
to survive in one of the harshest and least hospitable niches
in the human body. Gastric acidity acts as a formidable first
line of defence against food-borne pathogens, and the
constant outpouring of gastric secretions, coupled with
regular peristalsis, ensure that gastric contents, including
microbial agents, are constantly flushed away. Despite this,
H. pylori seems well equipped and adapted for habitation
within this harsh environment. Recent studies show that
H. pylori maintains its periplasmic pH within viable limits
through possession of an acid-induced urea channel that
regulates intra-bacterial urease activity.10,11 Essential nourish-
ment for H. pylori is drawn from host gastric tissue through
the inflammatory exudate it induces.12
Since its original description and culture by Marshall and
Warren in 1982,13 H. pylori has been causally implicated
in a variety of gastric diseases including simple gastritis,
gastric and duodenal ulcer disease, and gastric cancer. While
the link between H. pylori and peptic ulcer disease was
established soon after successful culture of the bacterium,
the association with gastric cancer lagged almost a decade
before credible evidence was presented. The major reason
for this delay was inability to demonstrate the presence of
active infection in gastric tissue of cancer patients. In order
to understand how this bacterium can predispose to such
variable clinical outcomes, it is necessary to understand
the basic pathophysiological consequences of its presence
within the human stomach. 
H .  P Y L O R I A N D  C H R O N I C  G A S T R I C
I N F L A M M A T I O N
The key pathophysiological event in H. pylori infection is
the initiation of an inflammatory response.14 This response
is most probably triggered by the bacterium’s lipopoly-
saccharide, urease, and/or cytotoxins and is mediated by
cytokines. Cytokines, including the interleukins, are soluble
peptide molecules that mediate the interaction between
immunocompetent and haematopoietic cells and between
the immune and neuroendocrine systems.15 They are pro-
duced by a variety of activated cells and exert their biological
effects through binding to specific receptors on target cells.
The cytokine repertoire comprises a multitude of pro- and
anti-inflammatory mediators whose function is to coordinate
an effective immune/inflammatory response against
invading pathogens without causing undue damage to
the host. 
In addition to their pro- or anti-inflammatory properties,
some H. pylori-induced cytokines have direct effects on
gastric epithelial cells that have a profound effect on gastric
physiology. For example, the proinflammatory cytokine
interleukin-1 beta (IL-1) is the most potent of known agents
that are gastric cytoprotective, antiulcer, antisecretory, and
inhibitory of gastric emptying.16 Wolfe and Nompleggi
estimated that on a molar basis, IL-1 is 100 times more
potent than both prostaglandins and the proton pump
inhibitor omeprazole and 6000 times more potent than
cimetidine in inhibiting acid secretion.17 Another important
proinflammatory cytokine that is upregulated by H. pylori
infection is tumour necrosis factor alpha (TNF-), which
also inhibits gastric acid secretion, but to a lesser extent
than IL-1.
In physiological terms, the stomach could be divided into
two main compartments: an acidic proximal corpus that
contains the acid-producing parietal cells, and a less acidic
distal antrum that does not have parietal cells but contains
the endocrine cells that control acid secretion.18 H. pylori
infection is first established in parts of the stomach that
have a higher pH such as the antrum. This is most likely
due to the bacterium’s attempt at energy preservation, for
although H. pylori is well equipped for survival at low pH,
this is achieved at a high cost of energy expenditure. Thus,
high acid production by the parietal cells probably protects
the corpus mucosa from initial colonisation. Both animal and
human ingestion studies suggest that successful colonisation
of the gastric mucosa is best achieved with the aid of acid
suppression.19-21 Furthermore, pharmacological inhibition
of acid secretion in infected subjects leads to redistribution
of the infection and its associated gastritis from an antral
to a corpus-predominant pattern.22-24 Thus lack of gastric
acid extends the area of colonisation and also maximises
the tissue damage resultant from this colonisation. 
H .  P Y L O R I I N F E C T I O N  A N D  T H E
D I V E R G E N T  C L I N I C A L  O U T C O M E S  
H. pylori infection is associated with divergent clinical
outcomes that range from simple asymptomatic gastritis
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to more serious conditions such as peptic ulcer disease and
gastric neoplasia. The extent of this remarkable divergence
is made more striking by the observation that certain out-
comes of the infection, such as duodenal ulcer disease,
are actually protective against others, such as gastric cancer.25
The key determinants of these outcomes are the severity
and distribution of the H. pylori-induced gastritis. There
are three main gastric phenotypes that result from chronic
H. pylori infection: (1) the commonest by far is a mild
pangastritis that does not affect gastric physiology and is
not associated with significant human disease, (2) a corpus-
predominant gastritis associated with gastric atrophy,
hypochlorhydria and increased risk of gastric cancer,26 and
(3) an antral-predominant gastritis associated with high
gastric acid secretion and increased risk of duodenal ulcer
disease.27 The association of H. pylori with such variable
outcomes poses a most fascinating scientific challenge,
the unravelling of which will not only explain how ulcers
and gastric cancer develop, but will also act as a paradigm
for gene-environment interactions in most human diseases. 
H .  P Y L O R I I N D U C E S  V A R I A B L E  
G A S T R I C  P H E N O T Y P E S :  T H E  
G A S T R I C  C A N C E R  V E R S U S  
D U O D E N A L  U L C E R  P H E N O T Y P E S
There is accumulating evidence that acid secretory capacity
is crucial in determining the distribution and natural history
of H. pylori infection.18 In hosts with low secretory capacity
(genetically determined or secondary to pharmacological
inhibition) the organism is capable of colonising a wider
niche than would be possible in the presence of high
volumes of acid. Colonisation of a wider niche, including
the corpus mucosa, leads to corpus gastritis with resultant
functional inhibition of acid secretion. This inhibition is
mediated by H. pylori-induced inflammatory cytokines (such
as IL-1 and TNF-) and the net effect is the establishment
of a more aggressive gastritis that accelerates the develop-
ment of gastric atrophy. Once atrophy develops, acid
secretion is not only attenuated by the functional inhibition
caused by inflammatory mediators but by a more permanent
morphological change that is harder to reverse. This situation
is very relevant to the subgroup of humans who develop
the gastric cancer phenotype in the presence of chronic
H. pylori infection.
In contrast to subjects who have an increased risk of gastric
cancer, subjects who develop duodenal ulcer disease are
known to have a large parietal cell mass that is relatively
free of H. pylori-induced inflammatory activity. This pattern
of antral-predominant gastritis with high acid output
characterises the duodenal ulcer diathesis. The high acid
output is associated with the development of duodenal
gastric metaplasia (DGM), a protective mechanism against
the persistent delivery of an increased acid load to the
duodenum. The presence of gastric epithelium (DGM) in
the duodenum is an invitation for antral H. pylori infection
to colonise this new niche. The ensuing gastritis with the
production of proinflammatory cytokines such as IL-1
and TNF- greatly weakens the resistance of this mucosa,
and in the presence of large volumes of acid, and a reduction
in duodenal mucosal bicarbonate production,28 ulcers
develop.
As mentioned above, the effect of acid secretion on changing
the distribution of H. pylori colonisation and gastritis is most
markedly exposed in subjects in whom acid secretion is
manipulated by pharmacological means. Thus H. pylori-
infected subjects on long-term proton pump inhibitors
undergo a shift in the pattern of gastritis from antral- to
corpus-predominant, and they have a higher risk of develop-
ing gastric atrophy, a precursor lesion for gastric neoplasia.23
This observation provided a clue as to the role of potential
endogenous substances that could also inhibit acid secretion,
such as IL-1 and TNF-. As will be discussed later, these
two cytokines were prime candidates as host genetic factors
that may increase risk of gastric cancer. IL-1 is the arche-
typal pleiotropic cytokine being produced by many cells
and exerting its biological effects on almost all cell types.29
IL-1 is a very potent proinflammatory cytokine and is
involved in the host’s response to many antigenic challenges.
G E N E T I C  P O L Y M O R P H I S M S  I N  T H E
I L - 1 G E N E  C L U S T E R  I N C R E A S E  T H E
R I S K  O F  G A S T R I C  C A N C E R  A N D  I T S
P R E C U R S O R S
The key question in H. pylori research is how this infection
could be associated with such divergent clinical outcomes
as gastric cancer and duodenal ulcer disease. A large volume
of research has focused on the role of bacterial virulence
factors in the pathogenesis of these diseases, and although
these factors undoubtedly contribute to the degree of tissue
damage, they do not distinguish between the two key out-
comes.30 This prompted us to concentrate on the host
genetic factors that may be relevant to this process. The
search for the appropriate candidate genes had to stem
from a profound understanding of gastric physiology and
how it is disrupted by H. pylori infection. Since H. pylori
achieves most of its damage through induction of chronic
inflammation, it was reasonable to consider genes that
control this process as appropriate candidates.
The IL-1 gene cluster on chromosome 2q contains three
related genes within a 430 kb region, IL-1A, IL-1B and
IL-1RN, which encode for the proinflammatory cytokines
IL-1 and IL-1 as well as their endogenous receptor antag-
onist IL-1ra, respectively.31 IL-1 is upregulated in the pre-
sence of H. pylori and plays a central role in initiating and
amplifying the inflammatory response to this infection.32-34
IL-1 is also an extremely potent inhibitor of gastric acid
secretion;35,36 on a molar basis it is estimated to be 100-fold
more potent than proton pump inhibitors and 6000-fold
more potent than H2-antagonists.
37 Three diallelic poly-
morphisms in IL-1B have been reported, all representing
C-T transitions, at positions -511, -31, and +3954 bp from
the transcriptional start site.38 There are conflicting data
regarding the functional effects of these polymorphisms
on IL-1 production.39,40 The IL-1RN gene has a penta-allelic
86 bp tandem repeat (VNTR) in intron 2, of which the less
common allele 2 (IL-1RN*2) is associated with a wide range
of chronic inflammatory and autoimmune conditions.38
IL-1RN*2 is associated with enhanced IL-1 production in
vitro,40 but data regarding its effects on IL-1ra production are
contradictory.41-43 The gene also has a number of functionally
relevant polymorphisms that could be correlated with high
or low IL-1 production. This provided an ideal opportunity
to design the appropriate hypothesis-driven epidemiological
studies. 
We first studied the correlation of these high IL-1 geno-
types (two polymorphisms in the IL-1B and IL-1RN genes)
with hypochlorhydria and gastric atrophy in a Caucasian
population of gastric cancer relatives. These relatives are
known to be at increased risk of developing the same cancer
and have a higher prevalence of the precancerous abnor-
malities, but only in the presence of H. pylori infection. We
found that the high IL-1 genetic markers significantly
increase the risk of these precancerous conditions. In a
logistic regression model including both genotypes, the
estimated age-adjusted odds ratios for IL-1B-511/-31)*2+ and
IL-1RN*2/*2 were 7.5 (95% CI: 1.8-31) and 2.1% (95% 
CI: 0.7-6.3 respectively).44 We proceeded to examine the
association between the same IL-1 genetic polymorphisms
and gastric cancer itself utilising another Caucasian case-
control study comprising 366 gastric cancer patients and
429 population controls. We confirmed the same positive
association between these genotypes and gastric cancer. In
a logistic regression model including both genotypes, the
estimated odds ratios for IL-1B-511/-31T+ and IL-1RN*2/*2
were 1.6 (95% CI: 1.2-2.2) and 2.9 (95% CI: 1.9-4.4)
respectively.44
Although IL-1 was the perfect candidate gene, other genes
involved in the H. pylori-induced gastritis cascade are also
legitimate targets. Our most recent search has confirmed
a positive but weaker role for polymorphisms in the TNF-A
gene that correlate with high TNF- levels (El-Omar et al.,
unpublished data). The TNF- polymorphism increases
the risk of gastric cancer and its precursors in a similar
fashion to the IL-1 polymorphisms. This proinflammatory
cytokine is also upregulated in H. pylori infection and has
acid-inhibitory properties, albeit weaker than IL-. So it is
clear that the targeted and hypothesis-driven search for these
host genetic factors will aid in unravelling the pathogenesis
of H. pylori-related diseases. 
But how do these IL-1/TNF- polymorphisms explain the
divergent outcome to H. pylori infection? We speculate that
the effect of these polymorphisms operates early in the
disease process and requires the presence of H. pylori
infection. When H. pylori infection challenges the gastric
mucosa, a vigorous inflammatory response with a high
IL-1/TNF- component may appear to be beneficial, but
it has the unfortunate side effect of switching acid secretion
off, thus allowing the infection to extend its colonisation
and damaging inflammation to the corpus mucosa, an
area that is usually well protected by secretion of acid. A
decreased flow of acid will also undermine attempts to
flush out these toxic substances, causing further damage
to the mucosa. More inflammation in the corpus leads to
more inhibition of acid secretion and a continuing cycle
that accelerates glandular loss and onset of gastric atrophy.
It is apparent that this vicious cycle ultimately succeeds
in driving the infection out, but at a very high price for
the host. This is amply demonstrated by the finding that
H. pylori density becomes progressively lower with the
progression from mild gastritis through severe gastritis,
atrophy and intestinal metaplasia. Indeed, by the time gastric
cancer develops, it is extremely hard to demonstrate any
evidence of the infection.45
R O L E  O F  E N V I R O N M E N T A L  F A C T O R S
I N  G A S T R I C  C A R C I N O G E N E S I S
A very obvious question at this juncture is why only a few
H. pylori-infected subjects with these polymorphisms
develop gastric cancer. Why isn’t everyone with such a
genetic makeup at risk of this outcome? The answer lies
in the polygenic and multifactorial nature of most complex
human diseases. These genetic factors operate only in the
presence of an infectious agent and lead to the development
of an atrophic phenotype. Progression of atrophy towards
cancer depends on other components of the host genetic
constitution acting epistatically, as well as dietary and other
factors in the environment. While H. pylori infection and
host genetics interact to initiate a hypochlorhydric and
atrophic phenotype, environmental co-factors may mediate
subsequent neoplastic transformation, even after disappear-
ance of the infection. Diet may be particularly relevant,
with greater consumption of fresh fruits and vegetables
shown to protect against the risk of gastric as well as several
other cancers. Dietary vitamin C reduces the formation of
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N-nitroso-compounds and scavenges mutagenic reactive
oxygen metabolites generated by gastric inflammation,46
and supplemental vitamin C is associated with significantly
lower risk of noncardia gastric cancer.47 Furthermore,
vitamin C concentrations and bioavailability are reduced
in the presence of H. pylori infection.48,49 Another important
co-factor is cigarette smoking, which was found to nearly
double the risk of transition from atrophic gastritis to
dysplasia in a high-risk population.50 Thus, cytokine gene
polymorphisms represent only one component of a complex
interplay among host, pathogen, and environmental factors
involved in gastric carcinogenesis.
These proinflammatory polymorphisms, therefore, can
distinguish between subjects who will develop the hypo-
chlorhydric atrophic phenotype in response to H. pylori
infection and those who will manage to limit the infection
to a smaller area and offer relatively better protection of
their corpus function. Another valid question is whether
these proinflammatory polymorphisms actually offer
protection against the other extreme clinical outcome,
namely, duodenal ulcers. Could it be that a low IL-1/TNF-
response to H. pylori infection, and a consequently lower
inhibition of acid secretion, is the determinant of the
antral-predominant, corpus-sparing gastritis pattern seen
in duodenal ulcer patients? To date, no reports have been
published addressing this specific question. It would be
tempting to speculate that this would be the case, but my
gut feeling is that the large parietal cell mass frequently
seen in duodenal ulcer patients is determined by other
genetic factors, hitherto undescribed, that relate to parietal
cell development and the endocrine receptors they express.
This genetically determined capacity to secrete large volumes
of gastric acid will probably neutralise any subtle contribu-
tion of a genetic polymorphism in a cytokine gene.
C O N C L U S I O N S  A N D  A  L O O K  T O  T H E
F U T U R E
IL-1 is a very important proinflammatory cytokine with
profound effects on gastric physiology. Its acid-inhibitory
properties uniquely qualify it as a major player in the host’s
response to H. pylori infection and the diseases associated
with it. Polymorphisms in the gene for IL-1 that correlate
with higher levels of this cytokine have been found to
increase the risks of hypochlorhydria and gastric atrophy
in response to H. pylori infection and to increase the risk
of gastric cancer itself. These host genetic factors that
affect IL-1 may determine why some individuals infected
with H. pylori develop gastric cancer while others do not.
Future research should focus on identifying the molecular
pathways that mediate this increased risk. The search for
other host genetic factors that contribute to the pathogenesis
of the disease should continue, particularly in view of the
wonderful new opportunities made possible by the human
genome project. A special effort should be directed at
understanding these host genetic factors in non-Caucasian
populations, and in populations with high and low incidences
of gastric cancer. We should also target other upper GI
diseases that may be linked indirectly to these genetic
polymorphisms that alter gastric physiology. Prime amongst
these are oesophageal cancers and gastro-oesophageal reflux
disease.
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Van der Meer: Being a person who performs research with
interleukin-1, I would be interested to hear why you left
interleukin-1 out. Conceptually, IL-1 would also be an
interesting candidate. I wonder if you did consider that
and if you have data on it?
El-Omar: It is a very good point. We did not ignore inter-
leukin-1. IL-1 does not have any effect whatsoever on
this particular model.
Kimman: Your genetic data appear very convincing, but are
they supported by physiological data? Do people with a pro-
inflammatory genotype really have higher IL-1 levels in their
gastric lesions than people with a less inflammatory genotype?
El-Omar: Polymorphism has to be functional. There are some
data showing these proinflammatory genotypes to be associ-
ated with higher IL-1 levels, but it is pretty weak. The IL-1
receptor antagonist is probably the strongest. Allele 2 of
that VNTR polymorphism is probably the strongest that we
have. It is actually very difficult to measure the cytokine
content and correlate that with genetic polymorphisms.
In the presence of the infection, depending on the severity,
it may be quite difficult to correct for the degree of inflam-
mation in that particular locus. We lack tools to address this
question appropriately and we are lagging behind in terms
of explaining the physiological effects of these polymorph-
isms, but the epidemiological data are pretty powerful.
Netea: IL-1 receptor antagonist is approved for treatment of
rheumatoid arthritis and anti-TNF treatments have already
been in use for a couple of years. Is there anything known
about whether this pattern of gastric pathology is changing
in some of the patients who also have Helicobacter infections?
El-Omar: A very interesting question. We have not been
studying this. Rheumatologists are probably not going to
look for changes in the stomach. It is a very worthy experi-
ment to perform, perhaps in an animal model.
Netea: Would patients with a duodenal ulcer, who receive
anti-TNF for rheumatoid arthritis, get worse as a result of
the treatment?
El-Omar: Nothing is known about that, but people with
rheumatoid arthritis who get ulcers usually get them because
of nonsteroidal anti-inflammatory drugs. So you are dealing
with two different issues, which makes it difficult.
Van der Meer: The nonsteroidal anti-inflammatory drugs
should inhibit prostaglandins and thereby upregulate
cytokine production. So you get into complicated counter-
regulatory mechanisms.
El-Omar: And the link between the effect of NSAIDs and
H. pylori is very controversial.
Van Deuren: It is even more complicated, because IL-1
upregulates cortisol. High IL-1 producers may have higher
cortisol levels and therefore a higher acid secretion. On the
other hand IL-1 would decrease acid secretion. Physiological
tests would be decisive, I think. 
El-Omar: I do not think experiments have been conducted
that address these questions. 
Van Deuren: We are often considering whether we should
perform a repetitive gastroscopy in patients with atrophic
gastritis and if so, how many times – once every three years,
once or twice a year? Do you envisage that in the future,
genetic make-up will be decisive in the scheme for endo-
scopic control?
El-Omar: It is of course much simpler to test for HP infection
and if you find it, get rid of it. The genetic make-up becomes
unimportant. The value of these genetic studies and genetic
markers, from my point of view, is in understanding the
pathogenesis. 
Kusters: Clearly there are markers for severity and for suscep-
tibility. Could it be that your population is biased regarding
the susceptibility to infection with H. pylori and how would
that affect your data?
El-Omar: What I have shown is that these markers influence
the severity and the outcome of the infection, not necessarily
the susceptibility. We looked at susceptibility originally and
found that high IL-10 genotypes will increase the risk of
contracting a chronic H. pylori infection. This suggests that
an anti-inflammatory Th2-driven response allows this
infection to persist. We found this in two populations in
two studies, but in a third, much larger study I could not
reproduce the same data, and that made me reluctant to
claim that high IL-10 genotypes increase the risk of acquiring
the infection. However, mice that consecutively produce more
IL-10 have persistent Helicobacter infection, while mice with
a vigorous Th1-driven cytokine response clear the infection. 
Discussion following lecture by E.M. El-Omar
Appelmelk: I can understand how inflammation shuts down
acid production, but I am puzzled how a shutdown of acid
would act the other way around. In your view, the cause is
the shift of the bacteria from antrum to corpus, but what
is the evidence? In the mouse colonisation is exclusively
localised in the antrum. Yet there is strong atrophy in the
corpus. Could you envisage a model where the bacteria are
not needed and still an acid-induced increased inflammation
occurs in the corpus?
El-Omar: There are only two experiments where people
have either ingested or acquired acute H. pylori infection.
When Marshall and Morris just took a preparation and
swallowed it, there was colonisation only when they took
acid inhibitors. So it looks as though you have to switch
off the acid secretion to allow the bacteria to take hold in
the stomach. The other fact is that when H. pylori is first
acquired, it tends to settle in the less acidic parts of the
stomach. That is why you get maximal colonisation in the
antrum. Although Helicobacter is unique in surviving in
an acidic environment, it is at the cost of high energy
expenditure. It has to use a lot of its machinery to try and
protect itself from the acid exposure. Acid secretion seems
to determine how extensive the colonisation in the stomach
will be. Now, if interleukin-1 is poured out to fight this
infection and at the same time acid secretion is switched
off, the infection does extend from the antrum to the corpus
leading to a more severe corpus gastritis. But the counts
are probably even slightly reduced in both areas. What is
happening here is a pouring out of acid from the glands
trying to flush out all the toxins and all the mediators. If
the acid secretion is switched off, you have basically got a
dry part of the stomach where maximal concentrations of
these damaging genotoxic substances can exert their effect.
McAdam: In West Africa the babies seem to be getting
infected at weaning or before. By the age of one, using
noninvasive tests, we have a Helicobacter infection rate of
approximately 80%. This has been ascribed to all sorts of
things, but certainly to malnutrition. Around the age of
weaning these children start losing weight. What is the
natural history when Helicobacter infects people from the
age of one for the rest of their lives? 
El-Omar: Theoretically, if the infection is acquired at a much
earlier age, at the time when the stomach is not fully
developed in terms of its acid secretion, the phenotype
should be more in keeping with the gastric atrophy and
low acid secretion and that should increase the risk of
developing gastric cancer. In addition, the Africans tend
to have a so-called proinflammatory genetic make-up. Yet
we do not see such a dramatic increase in gastric cancer.
Whether they do not live long enough to develop it, or
whether there are other conditions that are modifying the
inflammatory response, has not been addressed. One very
interesting experiment came from Fox et al.1 They looked
at the role of co-infection with helminths. It showed that
in an animal model, if you co-infect with a helminth the
system tries to switch the immune response from a Th1 to
a Th2, which attenuates your inflammatory response and
prevents gastric atrophy. It may be that in these populations,
where you have such a high prevalence of H. pylori, yet you
have very little clinical disease, there are other factors,
other bacteria that may be modulating this inflammatory
response.
Peña: There is a great difference between duodenal ulcer
and gastric ulcer. There are families that either develop
gastric ulcers or duodenal ulcers. Did you study this kind
of polymorphism?
El-Omar: It is fascinating that in the West duodenal ulcer
and gastric cancer so seldom both strike in one patient.
Classically, the people who develop gastric cancer are the
ones in whom there has been manipulation of acid secretion:
they either have had a vagotomy or surgery that basically
attenuates their acid production. Some people would argue
that inhibition of gastric acid over many years could be
the reason why these people basically switch from being
protected towards being at risk. Some fascinating data from
Japan2 recently showed that regarding the proinflammatory
genotype, this genetic constitution in people who have DU
disease at the beginning, at an early age, when they are in
their teens or in their early twenties, if you follow them long
enough, you will see very few people with this proinflam-
matory genotype actually having duodenal ulcer disease
or a relapse of duodenal ulcer disease. So it may increase
the risk at an early age, but it burns out, and the reason it
burns out is presumably because of the effects on the corpus
mucosa, discontinued inflammation, the onset of atrophy,
and eventually they basically become less protected against
gastric cancer and more likely to show the hypochlorhydria
atrophic phenotype. The question of looking at gastric
ulcers vs duodenal ulcers has not been addressed properly
and there is one study looking at the effect of these poly-
morphisms on peptic ulcer disease.3
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The clinical course of HIV infection
HIV-1 infection is characterised by a gradual and progressive
loss of CD4+ T cells, ultimately leading to the acquired
immunodeficiency syndrome (AIDS), which is characterised
by opportunistic infections, neurological symptoms and
malignancies. Among patients, the clinical course of HIV-1
infection is highly variable. Before antiretroviral therapy
became available, the asymptomatic phase of infection could
take only months (rapid progressors) or last for more than
15 years (long-term asymptomatics, LTA). Between these
extremes, the median time from infection to AIDS diagnosis
is eight to ten years.1
The course of HIV infection may be influenced by both viral
and host factors. The host fights infection by generating
HIV-specific cytotoxic T cells and antibodies. The error-
prone nature of HIV-1 reverse transcriptase results in the
generation of a spectrum of HIV-1 mutants in each replica-
tion cycle (viral quasi-species). The growth advantage of
mutants with altered antigenic structures (escape mutants)
allows the virus to escape from the suppressive action of
the immune system. The variable nature of HIV-1 also
results in the evolution of other biological characteristics,
such as replicative capacity, cytopathicity and cellular
tropism.
Though the significance of the humoral immune system
to protect against AIDS remains controversial, cytotoxic
CD8+ T cells have been shown to signifcantly influence
HIV-1 disease progression. Depletion of CD8+ T cells in
simian immunodeficiency virus (SIV)-infected macaques
leads to a rapid increase in viral replication.2 In humans,
the presence of CTL has been associated with reduced
viral load and a more benign disease course.3-5
The importance of the viral phenotype for HIV-1 patho-
genesis is supported by multiple studies: experimental
infection of macaques with late-stage SIV variants resulted
in a more rapid disease progression than infection with
early isolates;6 extremely slow progression of disease was
observed in haemophiliacs who were infected with an
attenuated virus that lacked the regulatory viral gene nef7;
and long-term nonprogressors more often harbour virus
variants with slow in vitro replication kinetics.8
Another aspect of the HIV-1 phenotype is the so-called
syncytium-inducing (SI) capacity. SI HIV-1 variants first
got their name as they are able to infect and induce fusion
of cells into multinucleate cells (syncytia) in T-cell lines,
due to their ability to use chemokine receptor CXCR4 as a
viral coreceptor (therefore SI HIV variants are also referred
to as X4 HIV-1 variants).9 Nonsyncytium-inducing (NSI)
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The outcome of HIV-1 infection is highly variable: not all individuals exposed to HIV-1 will become infected, and among
individuals who do become infected the time from infection to clinical AIDS is highly variable. This variability is thought
to reflect the complex interactions between virus and host. An important role for host genetic factors in the pathogenesis
of HIV-1 infection is increasingly being appreciated. Many novel genetic polymorphisms have been identified and analysed
for their role in HIV-1 transmission and disease progression. Here an overview is provided of polymorphisms in chemokines
and chemokine receptors that influence HIV-1 disease.
HIV-1 variants are in general restricted to CCR5 usage
(R5 HIV-1 variants). Whereas HIV-1 infection is in general
established by a homogenous population of macrophage
tropic NSI / R5 HIV-1 variants. SI / X4 HIV-1 variants may
evolve from these R5 variants in approximately half of the
HIV-1 infected patients. The emergence of these X4 variants
in patients is associated with a more rapid loss of CD4+ T
cell numbers and a more rapid progression to AIDS.10,11
Chemokines, chemokine receptors and HIV-1
Chemokines are small, structurally-related molecules
involved in chemotaxis of a large variety of cell types via
interaction with G protein coupled 7-transmembrane
spanning receptors. Chemokines play a role in a variety of
biological processes, such as lymphocyte migration to sites
of inflammation, migration through various lymphoid organs
during lymphocyte development and in angiogenesis.12-14 In
1996, chemokine receptors were identified as coreceptors
for entry of HIV-1 (for references see table 1). Viral entry is
a multistep mechanism, in which the envelope protein gp120
in succession binds to the CD4 molecule and a chemokine
receptor. This results in a series of conformational changes,
which eventually leads to fusion of the viral and cellular
membrane. Several members of the chemokine receptor
gene family have been identified as HIV-1 coreceptors
(table 1). Of these, CCR5 and CXCR4 are thought to be
the most relevant in vivo, whereas the in vivo role of the
additional chemokine receptors remains to be established.
Cellular tropism of HIV-1 variants is primarily determined
by coreceptor expression on the cell surface and coreceptor
preference of the virus. Thus, CCR5 expressing cells, such
as macrophages and memory CD4+ T cells, can be infected
by R5 variants, whereas CXCR4 expressing cells, such as
memory and naive CD4+ T cells, can be infected by X4
variants.15,16 Since naive cells are crucial in the process of
T-cell renewal, the capacity of X4 HIV-1 variants to infect
and eventually kill these cells may explain the more rapid
CD4+ T-cell decline associated with the presence of X4
HIV-1 variants. It should be noted that post-entry restrictions
on HIV-1 replication may also influence tropism, as shown
for macrophages and resting T cells, that may not efficiently
support HIV-1 replication despite expression of the appro-
priate coreceptors.17,18
The natural ligands of the HIV-1 coreceptors, MIP1a, MIP1b,
RANTES (ligands of CCR5) and SDF-1 (ligand of CXCR4),
have been shown to inhibit virus replication in vitro19-23 and
enhanced in vitro chemokine production by patient periph-
eral blood mononuclear cells (PBMC) has been associated
with slow disease progression.24,25 Furthermore, expression
levels of CCR5 have been shown to influence infectibility
in vitro.26,27 Therefore, it can be expected that genetic dif-
ferences that influence the pattern and level of expression
of chemokines and chemokine receptors may have a major
impact on the course of HIV-1 disease.
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Table 1
Chemokine receptors and structurally related molecules shown to mediate entry of HIV-1 into CD4+ cells
CHEMOKINE RECEPTOR LIGAND NEW REFERENCEC
RECEPTOR NOMENCLATURE 
FAMILYa FOR LIGANDb
CC CCR2 MCP1-4 CCL2, CCL8, CCL7, CCL13 105
CCR3 Eotaxin, Eotaxin-2, CCL11, CCL24, CCL5, CCL3 105,106
RANTES, MIP1a
CCR5 MIP 1a MIP 1b RANTES CCL3, CCL4, CCL5 21,105-108
CCR8 I-309 CCL1 109,110
CCR9 TECK CCL25 111
CXC CXCR4 SDF-1 CXCL12 112
CXCR6/BONZO/ CXCL16 113,114
STRL33d
CX3C CX3CR1 Fractalkine CX3CL1 109,115
Orphan BOB/GPR15 Unknown 113,116
GPR1 Unknown 116
APJ Unknown 111,117
ChemR23 Unknown 118
Chemoattractant receptor BLTR LTB4 119
Virally encodede US28 Broad spectrum of CC 109,120
Chemokines, fractalkine
aChemokines can be divided into four families on the basis of the spacing between two N-terminal cysteines. Chemokine receptors are named according to the family
of chemokines they bind. bA new nomenclature for chemokines based on chemokine family names, which consists of family name (C, CC, CXC, CX3C), L (for
ligand) and the numbering of the respective gene, has recently been proposed.13,121 cReferences for the papers first to describe the molecule as an HIV-1 coreceptor
are cited. dGiven the recent identification of a ligand and assignment of a systematic name for this molecule, alternative naming is also given. eThis chemokine
receptor is encoded by human cytomegalovirus.
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CCR5 D32
Soon after the identification of chemokine receptors as the
coreceptors for entry of HIV-1 into human CD4+ T cells,
individuals were identified who had frequently been exposed
to HIV-1, and yet remained uninfected due to a homozygous
genotype for an inactivating deletion of 32 base-pairs in the
CCR5 gene.28-30 This polymorphism in the CCR5 gene (CCR5
D32 leads to a premature frameshift and a nonfunctional
protein that is not expressed on the cell surface. As with
other polymorphisms, a large racial variation in the preva-
lence of the CCR5 D32 allele is observed. It is common
among Caucasians, whereas it is virtually absent in African-
Americans and Africans (table 2). The effects of CCR5 D32
on the course of HIV-1 disease have been widely studied,
though primarily in cohorts of subtype B-infected homo-
sexual men.31-34 In these studies, heterozygosity for CCR5
D32 has been associated with a delayed progression to AIDS.
In an international meta-analysis of individual patient data
from ten well-characterised cohorts of seroconverters, a
relative hazard of 0.74 for progression to AIDS was obtained
for CCR5 D32 heterozygosity.35 The mechanism of protection
most likely involves a reduction of the number of CCR5
positive cells and hence the number of potential target cells
for HIV-1, which may result in reduced virus replication
already during primary infection and subsequently a lower
viral set-point.36,37
In HIV-1-infected intravenous drug users, haemophiliacs
and recipients of contaminated blood28,38,39 no effect of
CCR5 D32 on disease progression was observed, whereas
a protective effect was observed among HIV-1-infected
children.40,41 It remains to be established whether this is
due to study design or whether the effect of CCR5 D32 is
indeed dependent on risk group and route of transmission.
CCR5 promoter
The CCR5 5’untranslated region (UTR) consists of three
exons and two introns. In this region, 12 single nucleotide
polymorphisms (SNPs) have been described,42-45 which
may, in part, explain differences in basal expression levels
of CCR5 among individuals homozygous for the wild-type
non-deleted CCR5 gene. To standardise the different
numbering systems for the CCR5 promoter in literature,
a numbering system was recently proposed in which the
first nucleotide of the translation start site is designated
as position 1, the nucleotide immediately upstream of this
position as position -1, and so on.46 In the paragraph below,
we will use this numbering system and show the alternative
nomenclature between brackets. 
Among SNPs in the promoter region of CCR5, a high degree
of linkage disequilibrium exists, allowing the identification of
four common haplotypes (P1 to P4) and six rare haplotypes
(P5 to P10), consisting of different combinations of 10 SNPs.45
The P1 haplotype, including T-2135C (alternative nomencla-
ture T627C, T59353C), was associated with a more rapid
course of disease. SNP G-2459A (alternative nomenclature
G59029A or G303A) was independently described to be
associated with a more rapid disease course.44 This SNP is in
complete linkage disequilibrium with the T-2135C47-49 and is
now considered to be part of the P1 haplotype. The asso-
ciation of these SNPs with enhanced disease progression
was observed in different risk groups, such as homosexuals,
haemophiliacs and perinatally-infected children.44,45,47-49 It
is likely that these SNPs or linked mutations are involved
in the regulation of transcription of CCR5, but results
from reporter assays have been inconsistent thus far.44,45
CCR2 64I
A valine-to-isoleucine transition in the second transmem-
brane region of CCR2 (CCR2 64I) has been associated with
a delayed progression to AIDS.50 The protective effect of
CCR2 64I is similar to the effect of CCR5 D32 (RH of
0.76 in meta-analysis of combined cohorts,35 results from
individual cohorts).31,32,34 Though the effect of CCR2 64I
on disease progression is obvious, the mechanism is still
not understood. CCR2 is rarely used as a coreceptor and the
mutated CCR2 molecule does not alter in vitro infectibility
of cells,51,52 therefore it is unlikely that the polymorphism
directly influences infection. The mutation in CCR2 is in
strong linkage disequilibrium with a single-nucleotide
polymorphism in the promoter of the CCR5 gene, C-1835T
(alternative nomenclature C927T or C59653T)42,43 and may
thus indirectly be involved in the regulation of expression of
CCR5. However, neither basal expression levels of CCR5 nor
transcription levels in primary lymphocytes were reduced in
CCR2 64I heterozygotes.51,52 An effect on CCR5 expression
has been suggested by the finding that re-expression of CCR5
after internalisation by N-terminal modified RANTES was
less rapid in two out of three CCR2 64I heterozygotes.53
An alternative explanation for the effect of CCR2 64I was
provided by Mellado et al., who showed that CCR2 64I pro-
tein was able to form dimers with CXCR4 after sensitisation
with the cognate chemokines, whereas the normal CCR2
protein was unable to do so.54 This capacity may thus reduce
the amount of CXCR4 available on the cell surface among
CCR2 64I carriers. This, however, does not explain the find-
ing that CCR2 64I already affects the viral load early in infec-
tion, when in general only NSI / R5 variants are present.55
CX3CR1 249I 280M
Although CX3CR1 is only used by a minority of HIV-1
variants as a coreceptor, an enhanced progression to AIDS
was observed among patients homozygous for CX3CR1
variant V249I T280M. These two amino acid substitutions
result in a reduced capacity to bind the cognate ligand
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fractalkine.56 The effect on the course of HIV-1 infection could,
however, not be confirmed in three US-based cohort studies.57
P O L Y M O R P H I S M S  I N  C H E M O K I N E S
A N D  H I V - 1  I N F E C T I O N
RANTES promoter
Beta-chemokines can block HIV-1 infection via CCR5 in
vitro19-21 and high production levels of these chemokines
have been associated with less rapid disease course.24,25
In vitro RANTES production levels can vary widely among
PBMC from different individuals, which in part may be due
to differences in the genetic make-up of the RANTES gene.
Two SNPs were identified within the RANTES promoter
region (C-28G and G-403A)58-60 and recently a variant in
intron 1 (In1.1C) was identified.61 These variants are in
strong linkage disequilibrium: almost all subjects who carry
In1.1C also carry -403A, whereas -28G always occurs in
combination with -403A / In1.1C. Both promoter SNPs dis-
play increased promoter activity,58,60 whereas In1.1C is asso-
ciated with a strong downregulation of promoter activity.61
In a cohort of Caucasian homosexuals the -403A -28C
haplotype was associated with a reduced progression of
disease,59 which could not be confirmed in an analysis of
five US-based cohorts.61 In the latter study, In1.1C was
associated with more rapid disease progression in both
Caucasians and African Americans.
SDF-1 3’A
Initially, a very strong protective effect was reported for
homozygosity for a G-to-A mutation in the 3’ untranslated
region of the SDF-1 gene (SDF-1 3’A),62 encoding the ligand
for CXCR4. This effect could not be confirmed in other
studies,42,63-67 including an international meta-analysis of
individual cohorts (RH=0.99).35
C H E M O K I N E  R E C E P T O R  P O L Y M O R P H -
I S M S  A N D  T H E  A C Q U I S I T I O N  O F
S I / X 4  H I V - 1  V A R I A N T S
The development of X4 / SI HIV-1 variants is a hallmark
of disease progression, and their appearance has invariably
been associated with a more rapid progression to
AIDS.10,11,68,69 It is still not understood why X4 variants
develop in some patients and not in others. Several factors
have been suggested to influence the development of X4
variants, including structural restrictions70 and loss of fitness
during the adaptive process of gp120,71 levels of proteins
that bind to CXCR4, such as SDF-123 and HIV-1 tat protein72,
and immune control.73 Recently it was shown that host
genetic factors may play a role in the appearance of X4
HIV-1 variants.
As compared with the CCR5 WT genotypic group, the acqui-
sition of SI variants was delayed in the group of CCR5 D32
heterozygotes. An unexpected finding was the association
of the CCR2 64I allele with an increased conversion rate
toward X4 variants.55,74,75 As this mutation is linked to the
promoter mutation in CCR5, enhanced X4 conversion may
be due to altered levels or patterns of CCR5 expression.
C H E M O K I N E  R E C E P T O R  P O L Y M O R P H -
I S M S  A N D  H I V - 1  T R A N S M I S S I O N
HIV-1 may be transmitted from mother to child, via sexual
contact, needle sharing, or exposure to contaminated blood
products. Exposure to HIV-1 does not invariably lead to
persistent infection. A multitude of factors influence
transmission rates, such as frequency and magnitude of
exposure, inoculum size, disease stage, CD4+ T cell numbers
and immune response of the patient.76-79 Early in infection,
a homogenous population of mainly macrophage tropic,
NSI / R5 virus variants can be found, suggesting a strong
selection pressure with regard to virus phenotype in acute
infection. Indeed, susceptibility of cells from the exposed
individual to R5 HIV-1 variants has been correlated with
transmission.80,81 One of the most prominent determinants
for transmission is the viral load in the donor, irrespective
of whether it involves homosexual, heterosexual, parenteral
or perinatal transmission.40,81-85
The role of host genetic factors in viral transmission is
typically studied in a case-control setting, in which the pre-
valence of a genetic marker in a population of HIV-1-infected
patients is compared with the prevalence of this marker
in an HIV-1-negative control group or, more extremely, with
a group of individuals who are known to have been exposed
to HIV-1, yet remain uninfected (exposed uninfected). There
has been considerable debate about the role of host genetic
factors in protection against transmission of HIV-1. Part
of these conflicting results may be due to differences in
the composition of the study population and selection of
the HIV-1-negative control group. Diverging results have
indeed been reported upon selection of highly exposed
uninfected individuals or nonexposed HIV-1-negative indivi-
duals as a control group.62,86 Furthermore, confounding
factors, such as viral load in donor, should preferentially
be taken into account in transmission studies.
Considerable efforts have been undertaken to study the
role of CCR5 D32 in transmission of HIV-1.
Homozygosity for CCR5 D32 has been associated with
protection from transmission in all risk groups studied.39,87-90
This indicates an absolute requirement for CCR5 in the
establishment of infection, irrespective of the route of
entry. Despite the near complete resistance, the few case
reports of infected CCR5 D32 homozygotes91-95 and the
identification of laboratory workers accidentally infected
with T cell line adapted, X4 restricted virus variants,96
indicate that transmission via X4 variants can occur in
selected cases. The role of CCR5 D32 heterozygosity in
protection from transmission has been more controversial.
Though protective effects of CCR5 D32 heterozygosity have
been reported,30,97 the majority of studies fail to show a
protective effect of CCR5 D32 heterozygosity on trans-
mission.28,37,40,87,88,90,98-100
Polymorphisms in RANTES (-G403A, -C28G, In1.1C),
the ligand for CCR5, were shown to be associated with
increased risk of homosexual transmission.59,61 This fits
the finding that CD4+ T cells from exposed uninfected
individuals express higher levels of MIP1a, MIP1b and
RANTES upon in vitro stimulation.20,101
Kostrikis et al. reported a significant increase of HIV-1
transmission to African-American infants homozygous
for a promoter allele CCR5 C-2132T (or CCR5 C59356T,
C630T).99 This mutation was rare in Caucasians and
Hispanics, and a potential role for this allele could not
be assessed in these children. John et al. showed that
maternal SDF 3’A heterozygosity was associated with an
increased risk in transmission, which was more pronounced
when transmission occurred via breastfeeding.102
C O N C L U D I N G  R E M A R K S
Our insights into the role of host genetic factors in the
course of HIV-1 infection are growing. However, it is
important to note that the majority of genetic factors
described so far only have a relatively mild influence on
the course of disease and can only partly explain differences
in disease course among patients. Of note, only a minority
of long-term nonprogressing HIV-1-infected individuals
carry known protective alleles and, conversely, the presence
of a protective allele does not warrant a benign disease
course. Furthermore, the majority of frequently exposed
but uninfected individuals do not contain CCR5 D32
homozygous or other protective genotypes, and therefore
other mechanisms, such as a potent CTL response or
reduced infectibility of CD4+ T-lymphocytes, may contribute
to the resistance to infection in these individuals.79,103,104
Without doubt, the identification of novel HIV-1 disease-
modifying genetic factors will be ongoing in the coming
years, yielding further insights into the complex interplay
between virus and host and the relative role of host genetic
factors therein. Besides expanding our understanding of
the pathogenesis of HIV-1 infection, this will hopefully
lead to the identification of critical targets for therapeutic
interventions. 
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Hoepelman: The first studies with anti-CCR5 antibodies
were performed in heavily pretreated AIDS patients.
Surprisingly, a rapid decline in the viral load is seen in these
patients. That decline persists at least 16 weeks. I would
have expected there would have been a rapid shift of the
virus, because many patients probably harbour R4 virus.
Do you think this is due to short follow-up or is there
another explanation?
Schuitemaker: When CCR5 is not properly functioning in
the CCR5 D32 heterozygotes, we see a protective effect,
even in individuals who have X4 viruses, so I guess you
achieve benefits by blocking only the R5-using population.
In really late-stage patients with very low CD4 counts, we
sometimes see a natural infection which the X4 viruses
do not survive, because at that time, X4 viruses mainly
use naive T cells as their targets, whereas R5 viruses use
memory cells and this leads to a depletion of naive T cells.
So it might be by this shift in the predator-prey relation
that at that time there are no longer any T cells that could
serve as target cells.
Hoepelman: My second question concerns the prostitutes
in Kenya who do not get infected. I thought this was due
to homozygosity for the deletion, but you stated you do
not see that in Africa. So what is the explanation?
Schuitemaker: These women are highly protected by cytotoxic
T lymphocytes and it is assumed that when these women
keep working, they are protected. There is continuous
antigenic stimulation of their immune system. However,
when they take a holiday, there is an increase in infection.
It is completely opposite to what was expected. 
De Marie: Persistent viraemia with a GB virus type C has
been recently recognised as a protective factor, even in HIV
patients treated with antiretroviral therapy. Did you study
the presence of these viruses in relation to the CR5 gene?
Schuitemaker: We are going to do that. It is very difficult
to set up a proper study, because the GBVC viraemia is
normally transient, and only viraemia is associated with a
protective effect. 
Discussion following lecture by H. Schuitemaker
De Groot: The disease course in perinatal infection is much
more rapid with incubation time of about a year. Is there
information on the expression of CCR5 on neonatal T cells? 
Schuitemaker: I am not aware of those data. HIV infection
being a viral disease, the loss of cells was thought to be a
result of virus-mediated killing. The more recent idea is
that it is chronic immune stimulation that consumes the
T cells, rather than virus-mediated killing. All cells go
through the process of becoming infected and dying a
natural death from apoptosis. And since neonates respond
more strongly to all kinds of infection, you can imagine
that HIV infection may have a more dramatic course.
Verbrugh: Since AIDS is a relatively new disease, the R5
polymorphism was presumably there before the virus hit
mankind and also the difference across the globe probably
was there as far as the dissolution of this polymorphism is
concerned. What would the role of this receptor have been
in other types of disease? 
Schuitemaker: When people ask me this question, I always
say that CCR5 protects you from the negative effects of
eating polar bears. I say this because in the northern
regions like Scandinavia there is up to 40% of that genotype.
SCCR5 is an activation marker and allows T cells to respond
to inflammation and lead to immunopathology. For some
infections it is not good to overreact. It is pure speculation,
but having this polymorphism could be advantageous. It is
of interest that individuals that are CCR5 D32 homozygous
have no record of immune deficiency.
Kimman: Is CCR5 used as a receptor by other pathogens?
I am thinking of endogenous retroviruses. Our genome
harbours many retroviruses. Have they used CCR5?
Schuitemaker: Not that I am aware of.
Van Strijp: The finding of a coreceptor may turn the main
receptor also into a coreceptor. Are there experiments with
overexpressing one of these receptors, CD4 or CCR5, to
see whether one of the receptors can do it on its own?
Which is the most important one?
Schuitemaker: It is possible to change the chemokine recep-
tor, but you need CD4 in addition. Therefore, CD4 is still
assumed to be the main receptor. So in artificial systems
you can use CCR5, but also CCR2 and CCR4 next to CD4,
and it works. However, HIV-2 virus can become CD4-
independent after passage, and also SIV, the related virus
in macaques, is very frequently CD4-independent. It could
very well be that the HIV was first using only chemokine
receptors and, after introduction into humans, the virus
adapted to using CD4 because of the proximity of CCR5
and CD4. High expression of the coreceptor does not
change the susceptibility of the cell and that CD4 is always
the limiting factor. That is also why macrophages are not
susceptible to SI / X4 viruses, despite the presence of
CXCR4 and CD4 on macrophages. When you upregulate
CD4, these cells become susceptible to X4 viruses. So it
seems that CD4 is the main receptor.
Kuijper: To give it a different perspective, the CCR5 D32
deletion seems also to be a susceptibility marker of asthma.1
I also have a question: Is there a difference in proliferative
potential between NSI and SI viruses? How easily do they
disseminate?
Schuitemaker: Among individuals dissemination of NSI
viruses is more efficient than of SI viruses. The viral load
however is not very different between NSI and SI carriers,
being slightly higher in SI individuals. The burst size of the
viruses, however, is different and SI viruses may be able to
kill cells earlier, thereby not allowing as much reproduction
as NSI viruses do. This more or less compensates for
the fact that SI viruses have more target cells, due to the
availability of more CXCR4 CD4 positive cells than CD4
CCR5 positive cells.
Kuijpers: So you take away the disseminating potential of
the NSI part? And this could perhaps explain the anti-CCR5
monoclonal effect?
Appelmelk: Where is the DC sign in your scheme with the
coreceptors?
Schuitemaker: DC sign is only expressed on dendritic cells.
It is still a matter of debate however whether DCs themselves
really become infected via DC sign or whether this molecule
only facilitates the infection of T lymphocytes. I know
that people have found polymorphisms in DC sign, but
considering the fact that I heard about this two years ago
and that nothing has been published on a correlation
between these polymorphisms and the clinical course, I
assume that there are no correlations.
Appelmelk: What happens to the virus when it makes these
new variants at a molecular level? Does it change its outside,
maybe in the sugar chains? Because, as you know, GP120
uses a ligand to attach to the DC sign.
Schuitemaker: Looking at the envelope, the variable domain 3
(the loop that sticks out and is important for the interaction
with the coreceptor) becomes more positively charged in SI
viruses. There are two specific amino acid residues in the
SI viruses at position 11 and 28. One or both are positively
charged in SI viruses.
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McAdam: You mentioned the differing use of receptors
for HIV-2. Could that account for the slowness of its
natural history and the low viral load?
Schuitemaker: HIV-2 is a very different story. Even when
you provide an optimal situation, the virus still hardly
grows, in contrast to HIV-1. I think something in the
genome attenuates the virus and therefore it takes so long
before the HIV-2 leads to disease. I think that it is not
just due to coreceptor use.
R E F E R E N C E
1. Sandford et al. J Allergy Clin Immunol 2001;108:69.
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